Professional Experience

advertisement
Curriculum Vitae for Meenhard Herlyn, D.V.M., D.Sc.
Meenhard Herlyn, D.V.M, D.Sc.
Updated: 3/18/15
Home Address
1223 Knox Road
Wynnewood, PA 19096
Office Address
The Wistar Institute
3601 Spruce Street
Philadelphia, PA 19104 USA
Tel.: 215-898-3950
Fax: 215-898-0980
Email: [email protected]
Web: http://www.wistar.org/lab/meenhard-herlyn-dvm-dsc
EDUCATION
1970
1976
D.V.M., Veterinary Medical School, Hannover, Germany
D.Sc., Medical Microbiology, University of Munich, Germany
POSTGRADUATE TRAINING AND FELLOWSHIP APPOINTMENTS
1971-1972
Fellowship in Immunology and Virology, University of Munich, Germany
1972-1976
Assistant at the Institute of Medical Microbiology, Infectious and Epidemic
Diseases, Veterinary Faculty, Maximillian University, Munich, Germany
1976-1979
Associate Scientist, The Wistar Institute, Philadelphia, PA
1979-1981
Research Associate, The Wistar Institute, Philadelphia, PA
1981-1985
Assistant Professor, The Wistar Institute, Philadelphia, PA
1986-1990
Associate Professor, The Wistar Institute, Philadelphia, PA
1991-present
Professor, The Wistar Institute, Philadelphia, PA
1991-1993
Chairman, Program of Experimental Therapeutics, The Wistar Institute,
Philadelphia, PA
1993-1998
Chairman, Program of Molecular and Cellular Biology, The Wistar Institute,
Philadelphia, PA
1998-2002
Chairman, Tumor Biology Program, The Wistar Institute, Philadelphia, PA
2002-2012
Leader, Molecular and Cellular Oncogenesis Program, The Wistar Institute,
Philadelphia, PA
2008-2011
Associate Director for Translational Research, The Wistar Institute
2010-present
Director, Melanoma Research Center, Philadelphia, PA
2011-present
Caspar Wistar Professor in Melanoma Research, Philadelphia, PA
FACULTY APPOINTMENTS
1982-1996
Consultant, Adjunct Associate Professor of Gynecology, Adjunct Professor of
Gynecology, Dept. of Gynecology, Division of Surgery, University of Texas, MD
Anderson Cancer Center, Houston, TX
1989-1991
Wistar Institute Associate Professor of Dermatology and Wistar Institute
Associate Professor of Pathology and Laboratory Medicine, University of
Pennsylvania, Philadelphia
1989-present
Member, Cellular and Molecular Biology Graduate Program (CAMB), University of
Pennsylvania, Philadelphia
1991- present
Member, University of Pennsylvania Comprehensive Cancer Center, Philadelphia
1992-present
Wistar Institute Professor of Dermatology and Wistar Institute Professor of
Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia
1995-2002
Member, Institute for Human Gene Therapy, University of Pennsylvania,
Philadelphia
1
Curriculum Vitae for Meenhard Herlyn, D.V.M., D.Sc.
2007-present
2011-present
Member, Bioengineering Graduate Group, University of Pennsylvania,
Philadelphia
Member, Institute for Regenerative Medicine, University of Pennsylvania,
Philadelphia
AWARDS AND HONORS
2004
Wings of Hope, Diana Ashby Award for Excellence in Melanoma Research
(Melanoma Research Foundation)
2005
American Skin Association Annual Skin Cancer/Melanoma Achievement Award
2006
Scientific Research Award for Outstanding Contributions in Melanoma Research,
American Cancer Society, Southeast Region, Pennsylvania Division
2006
7th Annual Wallace H. Clark, Jr., M.D., Lectureship in Cutaneous Oncology,
University of Pennsylvania, Philadelphia
2007
Pan American Pigment Cell Society Achievement Award
2007
Lifetime Achievement Award in Melanoma Research (Society for Melanoma
Research)
2008
28th Alfred-Marchioni Memorial Award, Hamburg, Germany
2008
Joseph-von-Plenck Award, Austrian Society for Dermatology and Venereology,
Vienna Austria
2010
Award for Lifetime Achievement in Melanoma Research (Society for Melanoma
Research)
2013
Rod and Ceil Mortel Visiting Scholar in Cancer Research, Penn State Milton S.
Hershey Medical Center, Penn State College of Medicine, Hershey, PA
2013
Founder’s Award (Society for Melanoma Research)
2014
International Skin Carcinogenesis Conference Keynote Lecture Award
2014
Wings of Hope, Humanitarian Award (Melanoma Research Foundation)
2015
American Skin Association, Life Time Research Achievement Award
MEMBERSHIPS IN: PROFESSIONAL AND SCIENTIFIC SOCIETIES (including offices held):
1982-present
American Association for Cancer Research
1996-2002, Pennsylvania Steering Committee
1997, Program Committee Chair, Biology
2004-2005, Stem Cell Initiative
1984-2010
American Association for Investigative Pathology
1995-present
Society for Investigative Dermatology
1999-present
Pan American Society for Pigment Cell Research
1999-2002, Council Member
1999-2002, Melanoma Group Chair
2000-2002, Membership Committee
1999-present
International Federation of Pigment Cell Societies
1999-2003, Special Interest Group on ‘Biology of Melanoma’ Chair
1985-present
American Association for the Advancement of Science
2000-present
Metastasis Research Society
2004-present
Society for Melanoma Research
2004-2007, Founder and President
2004-2007, Ex officio member of Executive Committee, Steering Committee
(Chair), Meeting Committee, Finance Committee, Election Committee,
Membership Committee
2007-2010, Past President, Member Steering Committee
2006-2011
Society for Stem Cell Research
2010-present
American Society for Clinical Oncology
EDITORIAL POSITIONS
1986-1988
Editorial Board, The Journal of Clinical Laboratory Analysis
1990-present
Associate Editor, Melanoma Research
2
Curriculum Vitae for Meenhard Herlyn, D.V.M., D.Sc.
1992-1998
1994-1999
1995-2003
1995-2002
1997-2004
1998-2000
2000-2007
2001-present
2002-present
2002-2007
2005-present
2005-present
2007-present
2007-present
2007-present
2007-present
2008-present
2008-present
2009-present
2010-2011
2012-present
2013-present
2013-present
2013-present
Editorial Board, Cell Growth and Differentiation
Associate Editor, Pigment Cell Research
Associate Editor, Journal of Experimental Therapeutics and Oncology
Editorial Board, Pathology Oncology Research
Editorial Board, American Journal of Pathology
Editorial Board, Tumor Targeting
Editorial Board, Cancer Research
Editorial Board, Cancer Biology and Therapy
Editorial Board, Cancer and Metastasis Review, 2005 Guest Editor
Associate Editor, Journal of Investigative Dermatology
Associate Editor, Pigment Cell and Melanoma Research
Editorial Board, International Journal of Cancer
Section Editor, Journal of Investigative Dermatology
Scientific Advisory Board, Journal of Cell Communication and Signaling
Consulting Editorial Board, Journal of Clinical Investigation
Editorial Board, Open Dermatology Journal
Editorial Board, Journal of Oncology
Editorial Board, Experimental Dermatology
Editorial Board, Genes & Cancer
Editorial Board, PLoS One
Editorial Board, Cancer Biomarkers
Editorial Board, Melanoma Management
Editorial Board, Precision Oncology
Advisory Board, International CCN Society
MANUSCRIPT REVIEWER
With major support from laboratory members, review of 110-170 manuscripts per year (2000-present)
for the American Journal of Pathology, Archives of Dermatology, Cancer, Cancer Cell, Cancer
Research, Cell, Clinical Cancer Research, Experimental Cell Research, International Journal of
Cancer, Journal of Cell Science, Journal of Clinical Investigations, Journal of Investigative
Dermatology, Journal of Immunology, Journal of Experimental Medicine, Laboratory Investigation,
Melanoma Research, Molecular Carcinogenesis, Nature, Nature Cell Biology, Nature Medicine, Nature
Review Cancer, Oncogene, Pigment Cell Melanoma Research, Proceedings National Academy of
Sciences (USA), and Science.
3
Curriculum Vitae for Meenhard Herlyn, D.V.M., D.Sc.
LECTURES BY INVITATION (past 5 years)
2010
Jan. 11
Jan. 14
Feb. 23
March 2
March 31
April 30
May 28
June 2
June 24
June 26
August 2
Sept. 12
Nov. 2
Nov. 5
Nov. 9
Dec. 14
2011
Jan. 12
Jan. 28
Feb. 2
Feb. 18
March 7
March 23
April 2-4
April 27
May 5
May 25
June 27
July 10
Nov. 29
Dec. 8
Dec. 16
2012
Jan. 19
Feb. 2
Feb. 21
April 1
May 10
June
June 12
June 18
June 22
July 27
University of Vienna, Vienna, Austria
L’Oreal, Paris, France
University of North Carolina, Chapel Hill, NC
University of Pittsburgh, Pittsburgh, PA
University of California at Irvine, Irvine, CA
Moffitt Cancer Center, Tampa, FL
Schering-Plough, Kenilworth, NJ
MD Anderson Cancer Center, SPORE Symposium, Houston, TX
GenoMEL, University of Leeds, Leeds, GB
Human Skin Carcinogenesis Symposium, Collegeville, PA
Roswell Park Memorial Institute, Buffalo, NY
AACR TME and Metastasis, Philadelphia, PA
Centenary Institute, University of Sydney, Sydney, Australia
SMR 7th International Conference, Sydney, Australia
Melanoma Symposium, Western Australia Institute for Medical
Research, Perth, Australia
University of Ohio, Cincinnati, OH
MD Anderson Cancer Center, Science Park, TX
L’Oreal, Paris, France
Adelson Medical Research Foundation, Las Vegas, NV
Melanoma Research Alliance, Washington, DC, Session Chair
AACR Special Conference on Stem Cells, Differentiations and Cancer,
Vancouver, Canada, Session Chair
Banbury Meeting on Curing Melanoma, Cold Spring Harbor Laboratory,
NY, Session Chair
AACR Annual Meeting, Orlando, FL
CSHL Symposium on Tumor Microenvironment, Cold Spring Harbor,
NY
Tetralogic, Malvern, PA
World Congress of Dermatology, Seoul, Korea
Engineered Tissue Models for Environmental Health Science Research,
NIEHS, Research Triangle Park, Chapel Hill, NC
European Post-ASCO Meeting, Munich, Germany
National Cancer Institute, Bethesda, MD
L’Oreal Inc., Paris, France
Expert Forum on Malignant Melanoma, Los Angeles, CA
Virginia Commonwealth University, Richmond, VA
Dartmouth School of Medicine, Dartmouth, NH
German Cancer Congress, Berlin, Germany, Keynote Lecture
American Association for Cancer Research, Annual Meeting, Major
Symposium Speaker
AACR Special Conference on Resistance Mechanisms to Targeted
Therapy, San Diego, CA
Melanoma Research Foundation Breakthrough Consortium, Chicago,
IL
Genentech, San Francisco, CA
GenoMEL Annual Symposium, Leiden, Netherlands
Pigment Cell and Melanoma Research Symposium, NCI, Bethesda,
MD
SPORE in Skin Cancer, Yale University, New Haven, CT
4
Curriculum Vitae for Meenhard Herlyn, D.V.M., D.Sc.
August 13
Sept. 5
2013
2014
Jan. 25
March 22
May 2
May 8
Sept. 5
Sept. 10
University of Cologne, Cologne, Germany
L’Oreal Inc., Paris, France
Sept. 17
Sept. 27
Nov. 20
Sandford-Burnham Institute, La Jolla, CA
German Cancer Society, Heidelberg, Germany
Hershey Medical Center, Hershey, PA, Award Lecture
International Melanoma Congress, Dublin, Ireland
Brazilian Workshop on Melanoma, São Paulo, Brazil, Keynote Lecture
European Organization of Pigment Cell Research, Lisbon, Portugal,
Keynote Lecture
L’Oreal Inc., Paris, France
Temple University, Philadelphia, PA
SMR 10th International Congress, Philadelphia, PA, co-organizer
Jan.
University
29
of
Febr. 27
March 9
April 5
April 11
April 25
June 5
Sept. 4
Sept. 22
Oct. 10
Oct. 13
University of Iowa, Iowa City, IO
Melanoma Research Alliance, Washington, DC
Tumor Progression and Therapeutic Resistance, Boston, MA
American Association for Cancer Research (AACR), San Diego, CA
HemOnc Today: Melanoma and Cutaneous Oncology, New York, NY
Georgia Regents University, Augusta, GA
International Skin Cancer Conference, Tucson, AZ, Keynote lecture
World Skin Cancer Congress, Edinburgh, GB
AACR Melanoma Conference, Philadelphia, PA
Australian Melanoma Conference, Perth, Australia, Keynote Lecture
University of Queensland, Brisbane, Australia
Feb. 10
Melanoma Club, Mt. Sinai, New York, NY
2015
ADVISORY ROLES (past 10 years):
2008-2011
MRF, Board of Managers, Member
2009
Jan., Southwestern Melanoma SPORE, Denver, CO, External
Advisor
Jan., PO1 Biotherapy of Metastatic Melanoma: Biology and Systemic
Delivery of MDA7/IL-24, (E. Grimm, PI), MD Anderson Cancer
Center, Houston, TX, External Advisor
Feb., Oct., NCI Study Sections, Tumor Microenvironment (TME), Ad
Hoc
May, NCI Intramural Review, Laboratory of Cancer Prevention
July, NCI, Stage II Challenge Grant Review Committee, Ad Hoc
Oct., Utah Skin SPORE, External Advisor
Feb.-Dec., Grant Reviews for Funding Agencies in Netherlands,
Austria, Australia, Germany, Israel, Great Britain
2010
Joanna M. Nikolay Melanoma Foundation, Advisory Board
NDRI, Board of Directors, Chair
NCI, Feb., Oct., TME Study Section, Member
NCI, Special Emphasis Panel, Chair
MRA, Grant Review Committee, Co-Chair
Roche, Washington, DC, Advisor
Moffitt Cancer Center, Tampa, FL, SPORE Advisor
MRF Breakthrough Consortium, Board of Directors
MRF Breakthrough Consortium, Secretary Treasurer
5
Curriculum Vitae for Meenhard Herlyn, D.V.M., D.Sc.
2011
Melanoma Research Alliance, Scientific Review Committee Co-Chair
June, Tumor Microenvironment Network Study Section, NCI, Chair
Sept., SPORE Study Section, Ad Hoc
Oct., TME NCI Study Section, Member
Jan.-Dec., Grant reviews from Austria, Germany, New Zealand, Israel,
Ireland, Netherlands, Norway
Grant Reviews for the Melanoma Research Foundation, Joanna
Nicolay Melanoma Foundation
NDRI, Board of Directors, Chair
MRF Breakthrough Consortium, Board of Directors
2013
Feb., Melanoma Research Alliance, Scientific Review Committee,
Member
May, NCI, Special Emphasis Panel, Ad Hoc Reviewer
April., Melanoma Research Foundation, Reviewer
August, Melanoma Research Foundation
NDRI, Board of Directors, Chair
MD Anderson, Skin SPORE
MRF Breakthrough Consortium, Board of Directors
SMR Congress 2013, Co-Organizer
Program Project, MD Anderson, L. Chin, PI
2014
Febr. Melanoma Research Foundation, Reviewer
April, Melanoma Research Foundation
NDRI, Board of Directors, Chair
MD Anderson, Skin SPORE
MRF Breakthrough Consortium, Board of Directors
Lung Cancer Spore, Denver, CO
FUNDING
Targeted Therapies in Melanoma
Principal Investigator: Meenhard Herlyn
Agency: National Cancer Institute
Type: PO1 (CA114046-03)
Years 5-10, Period: May 16, 2008 to Oct. 1, 2018
Subproject 1: Senescence as an endpoint in melanoma therapy
Human Melanoma: Etiology, Progression, and Therapy
Principal Investigator: Meenhard Herlyn
Agency: NIH/NCI
Type: P01-Program Project (CA25874),
Years 30-34, Period: May 1, 2011 to April 30, 2016
Subproject on grant: Cellular mechanisms of therapy resistance
Biology of Melanoma Metastasis
Principal Investigator: Meenhard Herlyn
Agency: National Cancer Institute
Type: R01 (CA47159)
Years 21-25, 2011-2016
Cell-Cell Communication During Melanoma Progression
Principal Investigator: Meenhard Herlyn
Agency: National Cancer Institute
Type: R01 (CA76674)
6
Curriculum Vitae for Meenhard Herlyn, D.V.M., D.Sc.
Years 15-19, Period: April 1, 2011 to March 31, 2016
The Role of Genetic Susceptibility in Melanoma Development
Principal Investigator: Meenhard Herlyn
Agency: National Cancer Institute
Type: R01 (CA182890)
Years 1-5, Period: May 1, 2014 to April. 30, 2019
SPORE in Skin Cancer
Principal Investigator: Meenhard Herlyn
Agency: National Cancer Institute
Type: SPORE (CA174523)
Years 1-5, Period: September 16, 2014 to September 15, 2019
CORE ACTIVITIES
1. Administrative Core A for Human Melanoma – Etiology, Progression & Therapy (CA025874)
2. Administrative Core A for Targeted Therapies in Melanoma (CA114046)
3. Administrative Core A for SPORE in Skin Cancer (CA174523)
4. Cell Biology Core C for Targeted Therapies in Melanoma (CA114046)
2013: Sponsored Agreements with industry (GSK, Novartis, Plexxikon, Tetralogic)
Dr. Miriam and Sheldon Adelson Foundation for Medical Research (2013/14)
Melanoma Research Alliance (Team Award) (2013-16)
Melanoma Research Foundation (2013/14)
BIBLIOGRAPHY
Research Publications, Peer Reviewed
1.
Buschmann H, Herlyn M. Stimulation of phagocytic activity by dextran. Z Immunitatsforsch Exp
Klin Immunol. 1972;143:209-210. PMID4282799
2.
Mayr A, Streitferdt U, Herlyn M, Jaeger O. Vaccination of dogs against rabies. Die Kleintierpraxis.
1973;18:91-96.
3.
Danner K, Herlyn M, Gerbermann H, Mayr A. Oral immunization against pox. 5: effectiveness of
drinking water vaccination against fowl pox. Zentralbl Veterinärmed B. 1975;22:274-284.
PMID169653
4.
Mahnel H, Herlyn M. Stability of Teschen, HCC, ND and vaccinia viruses against 5 disinfectants.
Zentralbl Veterinärmed B. 1976;23:403-411. PMID183417
5.
Mahnel H, Ottis K, Herlyn M. Stability in drinking and surface water of nine virus species from
different genera (author’s transl). Zentralbl Bakteriol [Orig B]. 1977;164:64-84. PMID14460
6.
Danner K, Luthgen K, Herlyn M, Mayr A. Comparative studies on the demonstration and formation
of serum antibodies against the Borna virus. Zentralbl Veterinärmed B. 1978;25:345-355.
PMID358683
7.
Koprowski H, Steplewski Z, Herlyn D, Herlyn M. Study of antibodies against human melanoma
produced by somatic cell hybrids. Proc Natl Acad Sci U S A. 1978;75:3405-3409. PMID80012
(PMC392785)
8.
Herlyn D, Herlyn M, Steplewski Z, Koprowski H. Monoclonal antibodies in cell-mediated
cytotoxicity against human melanoma and colorectal carcinoma. Eur J Immunol. 1979;9:657-659.
PMID499332
9.
Herlyn M, Steplewski Z, Herlyn D, Koprowski H. Colorectal carcinoma-specific antigen: detection
by means of monoclonal antibodies. Proc Natl Acad Sci U S A. 1979;76:1438-1442. PMID286328
(PMC383267)
10. Koprowski H, Steplewski Z, Mitchell K, Herlyn M, Herlyn D, Fuhrer P. Colorectal carcinoma
antigens detected by hybridoma antibodies. Somatic Cell Genet. 1979;5:957-971. PMID94699
7
Curriculum Vitae for Meenhard Herlyn, D.V.M., D.Sc.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
Steplewski Z, Herlyn M, Herlyn D, Clark WH, Koprowski H. Reactivity of monoclonal antimelanoma antibodies with melanoma cells freshly isolated from primary and metastatic
melanoma. Eur J Immunol. 1979;9:94-96. PMID374094
Herlyn M, Clark WH Jr, Mastrangelo MJ, Guerry DT, Elder DE, LaRossa D, Hamilton R, Bondi E,
Tuthill R, Steplewski Z, Koprowski H. Specific immunoreactivity of hybridoma-secreted
monoclonal anti-melanoma antibodies to cultured cells and freshly derived human cells. Cancer
Res. 1980;40:3602-3609. PMID6159966
Herlyn DM, Steplewski Z, Herlyn MF, Koprowski H. Inhibition of growth of colorectal carcinoma in
nude mice by monoclonal antibody. Cancer Res. 1980;40:717-721. PMID7471090
Wittek R, Herlyn M, Schumperli D, Bachmann PA, Mayr A, Wyler R. Genetic and antigenic
heterogeneity of different parapoxvirus strains. Intervirology. 1980;13:33-41. PMID6153643
Koprowski H, Herlyn M, Steplewski Z, Sears HF. Specific antigen in serum of patients with colon
carcinoma. Science. 1981;212:53-55. PMID6163212
Mayr A, Herlyn M, Mahnel H, Danco A, Zach A, Bostedt H. Control of ecthyma contagiosum
(pustular dermatitis) of sheep with a new parenteral cell culture live vaccine. Zentralbl
Veterinarmed B. 1981;28:535-552. PMID7331595
Sears HF, Herlyn D, Herlyn M, Grotzinger PJ, Steplewski Z, Gerhard W, Koprowski H. Ex vivo
perfusion of a tumor-containing colon with monoclonal antibody. J Surg Res. 1981;31:145-150.
PMID6790874
Steplewski Z, Chang TH, Herlyn M, Koprowski H. Release of monoclonal antibody-defined
antigens by human colorectal carcinoma and melanoma cells. Cancer Res. 1981;41:2723-2727.
PMID7248940
Atkinson BF, Ernst CS, Herlyn M, Steplewski Z, Sears HF, Koprowski H. Gastrointestinal cancerassociated antigen in immunoperoxidase assay. Cancer Res. 1982;42:4820-4823. PMID6751528
Brockhaus M, Magnani JL, Herlyn M, Blaszczyk M, Steplewski Z, Koprowski H, Ginsburg V.
Monoclonal antibodies directed against the sugar sequence of lacto-N-fucopentaose III are
obtained from mice immunized with human tumors. Arch Biochem Biophys. 1982;217:647-651.
PMID7138030
Herlyn M, Sears HF, Steplewski Z, Koprowski H. Monoclonal antibody detection of a circulating
tumor-associated antigen. I. Presence of antigen in sera of patients with colorectal, gastric, and
pancreatic carcinoma. J Clin Immunol. 1982;2:135-140. PMID7068815
Herlyn M, Steplewski Z, Atkinson BF, Ernst CS, Koprowski H. Comparative study of the binding
characteristics of monoclonal antimelanoma antibodies. Hybridoma. 1982;1:403-411.
PMID6765323
Sears HF, Herlyn M, Del Villano B, Steplewski Z, Koprowski H. Monoclonal antibody detection of
a circulating tumor-associated antigen. II. A longitudinal evaluation of patients with colorectal
cancer. J Clin Immunol. 1982;2:141-149. PMID7068816
Sears HF, Herlyn D, Herlyn M, Steplewski Z, Grotzinger P, Koprowski H. Ex vivo perfusion of
human colon with monoclonal anticolorectal cancer antibodies. Cancer. 1982;49:1231-1235.
PMID7059945
Thompson JJ, Herlyn MF, Elder DE, Clark WH, Steplewski Z, Koprowski H. Use of monoclonal
antibodies in detection of melanoma-associated antigens in intact human tumors. Am J Pathol.
107:357-361. PMID6177248 (PMC1916245)
Thompson JJ, Herlyn MF, Elder DE, Clark WH, Steplewski Z, Koprowski H. Expression of DR
antigens in freshly frozen human tumors. Hybridoma. 1982;1:161-168. PMID6208123
Folberg R, Donoso LA, Herlyn MF, Koprowski H. Antigens in ocular and cutaneous melanomas.
Am J Ophthalmol. 1983;96:394-395. PMID6351625
Hansson GC, Karlsson KA, Larson G, McKibbin JM, Blaszczyk M, Herlyn M, Steplewski Z,
Koprowski H. Mouse monoclonal antibodies against human cancer cell lines with specificities for
blood group and related antigens; characterization by antibody binding to glycosphingolipids in a
chromatogram binding assay. J Biol Chem. 1983;258:4091-4097. PMID6833243
Herlyn M, Herlyn D, Elder DE, Bondi E, LaRossa D, Hamilton R, Sears HF, Balaban G, Guerry D,
Clark WH, Kaprowski H. Phenotypic characteristics of cells derived from precursors of human
melanoma. Cancer Res. 1983;43:5502-5508. PMID6616481
8
Curriculum Vitae for Meenhard Herlyn, D.V.M., D.Sc.
30.
31.
32.
33.
34.
35.
36.
37.
38.
39.
40.
41.
42.
43.
44.
45.
46.
47.
Herlyn D, Powe J, Alavi A, Mattis JA, Herlyn M, Ernst CS, Vaum R, Koprowski H.
Radioimmunodetection of human tumor xenografts by monoclonal antibodies. Cancer Res.
1983;43:2731-2735. PMID6342757
Herlyn M, Steplewski Z, Herlyn D, Clark WH Jr, Ross AH, Blaszczyk M, Pak KY, Koprowski H.
Production and characterization of monoclonal antibodies against human malignant melanoma.
Cancer Invest. 1983;1:215-224. PMID6667406
Herlyn M, Blaszczyk M, Sears HF, Verrill H, Lindgren J, Colcher D, Steplewski Z, Schlom J,
Koprowski H. Detection of carcinoembryonic antigen and related antigens in sera of patients with
gastrointestinal tumors using monoclonal antibodies in double-determinant radioimmunoassays.
Hybridoma. 1983;2:329-339. PMID6205981
Mach JP, Chatal JF, Lumbroso JD, Buchegger F, Forni M, Ritschard J, Berche C, Douillard JY,
Carrel S, Herlyn M, Stepiewski Z, Koprowski H. Tumor localization in patients by radiolabeled
monoclonal antibodies against colon carcinoma. Cancer Res. 1983;43:5593-5600. PMID6616486
Ross AH, Cossu G, Herlyn M, Bell JR, Steplewski Z, Koprowski H. Isolation and chemical
characterization of a melanoma-associated proteoglycan antigen. Arch Biochem Biophys.
1983;225:370-383. PMID6614928
Steplewski Z, Herlyn M, Blaszczyk M, Koprowski H. A simple procedure for determining Lewis
phenotypes in human saliva. J Immunol Methods. 1983;62:73-78. PMID6348171
Zehngebot LM, Alexander MA, Guerry DT, Cines DB, Mitchell K, Herlyn M. Functional
consequence of variation in melanoma antigen expression. Cancer Immunol Immunother.
1983;16:30-34. PMID6605801
Atkinson B, Ernst CS, Ghrist BF, Herlyn M, Blaszczyk M, Ross AH, Herlyn D, Steplewski Z,
Koprowski H. Identification of melanoma-associated antigens using fixed tissue screening of
antibodies. Cancer Res. 1984:44:2577-2581. PMID6722794
Balaban G, Herlyn M, Guerry DT, Bartolo R, Koprowski H, Clark WH, Nowell PC. Cytogenetics of
human malignant melanoma and premalignant lesions. Cancer Genet Cytogenet. 1984;11:429439. PMID6584203
Blaszczyk M, Hansson GC, Karlsson KA, Larson G, Stromberg N, Thurin J, Herlyn M, Steplewski
Z, Koprowski H. Lewis blood group antigens defined by monoclonal anti-colon carcinoma
antibodies. Arch Biochem Biophys. 1984;233:161-168. PMID6465894
Blaszczyk M, Pak KY, Herlyn M, Lindgren J, Pessano S, Steplewski Z, Koprowski H.
Characterization of gastrointestinal tumor-associated carcinoembryonic antigen-related antigens
defined by monoclonal antibodies. Cancer Res. 1984;44:245-253. PMID6360346
Donoso LA, Folberg R, Angiolillo P, Herlyn M. A 19-9 monoclonal antibody study of
adenocarcinoma metastatic to the choroid. Am J Ophthalmol. 1984;98:815-816. PMID6507563
Ernst CS, Thurin J, Atkinson B, Wurzel H, Herlyn M, Stromberg N, Civin C, Koprowski H.
Monoclonal antibody localization of A and B isoantigens in normal and malignant fixed human
tissues. Am J Pathol. 1984;117:451-461. PMID6507589
Ernst CS, Atkinson B, Wysocka M, Blaszczyk M, Herlyn M, Sears H, Steplewski Z, Koprowski H.
Monoclonal antibody localization of Lewis antigens in fixed tissue. Lab Invest. 1984;50:394-400.
PMID6368970 (PMC1900579)
Guerry DT, Alexander MA, Herlyn MF, Zehngebot LM, Mitchell KF, Zmijewski CM, Lusk EJ. HLADR histocompatibility leukocyte antigens permit cultured human melanoma cells from early but
not advanced disease to stimulate autologous lymphocytes. J Clin Invest. 1984;73:267-271.
PMID6606651
Herlyn M, Sears HF, Verrill H, Koprowski H. Increased sensitivity in detecting tumor-associated
antigens in sera of patients with colorectal carcinoma. J Immunol Methods. 1984;75:15-21.
PMID6512262
Herlyn D, Herlyn M, Ross AH, Ernst CS, Atkinson B, Koprowski H. Efficient selection of human
tumor growth-inhibiting monoclonal antibodies. J Immunol Methods. 1984;73:157-167.
PMID6491298
Herlyn M, Lange B, Bennicelli J, Blaszczyk M, Guerry DT, Koprowski H. Increased levels of
circulating HLA-DR antigen in sera of patients with acute lymphoblastoid leukemia. Leuk Res.
1984;8:323-334. PMID6431198
9
Curriculum Vitae for Meenhard Herlyn, D.V.M., D.Sc.
48.
49.
50.
51.
52.
53.
54.
55.
56.
57.
58.
59.
60.
61.
62.
63.
64.
Herlyn M, Shen JW, Sears HF, Civin CI, Verrill HL, Goldberg EM, Koprowski H. Detection of a
circulating gastrointestinal cancer antigen in sera of patients with gastrointestinal malignancies by
a double determinant immunoassay with monoclonal antibodies against human blood group
determinants. Clin Exp Immunol. 1984;55:23-35. PMID6198117 (PMC1535790)
Miller SL, Pleasure D, Herlyn M, Atkinson B, Ernst CS, Tachovsky TG, Baird L. Production and
characterization of monoclonal antibodies to peripheral and central nervous system myelin. J
Neurochem. 1984;43:394-400. PMID6204014
Pak KY, Blaszczyk M, Herlyn M, Steplewski Z, Koprowski H. Identification and isolation of Lewis
blood group antigens from human saliva using monoclonal antibodies. Hybridoma. 1984;3:1-10.
PMID6469267
Pegg AE, Seely JE, Persson L, Herlyn M, Ponsell K, O’Brien TG. Studies of mammalian ornithine
decarboxylase using a monoclonal antibody. Biochem J. 1984;217:123-128. PMID6421279
(PMC1153189)
Ross AH, Grob P, Bothwell M, Elder DE, Ernst CS, Marano N, Ghrist BF, Slemp CC, Herlyn M,
Atkinson B, Koprowski H. Characterization of nerve growth factor receptor in neural crest tumors
using monoclonal antibodies. Proc Natl Acad Sci U S A. 1984;81:6681-6685. PMID6093111
(PMC391994)
Ross AH, Herlyn M, Ernst CS, Guerry D, Bennicelli J, Ghrist BF, Atkinson B, Koprowski H.
Immunoassay for melanoma-associated proteoglycan in the sera of patients using monoclonal
and polyclonal antibodies. Cancer Res. 1984;44:4642-4647. PMID6380710
Verrill H, Goldberg M, Kovac G, Atkinson B, Herlyn M. Evaluation of monoclonal antibody to 19-9
antigen as a potential screening technique for colorectal cancer in a high-risk population. Prog
Clin Biol Res. 1984;156:107-114. PMID6382320
Atkinson B, Ernst CS, Ghrist BF, Ross AH, Clark WH, Herlyn M, Herlyn D, Maul G, Steplewski Z,
Koprowski H. Monoclonal antibody to a highly glycosylated protein reacts in fixed tissue with
melanoma and other tumors. Hybridoma. 1985;4:243-255. PMID4043988
Blaszczyk M, Pak KY, Herlyn M, Sears HF, Steplewski Z. Characterization of Lewis antigens in
normal colon and gastrointestinal adenocarcinomas. Proc Natl Acad Sci U S A. 1985;82:35523556. PMID2582419 (PMC397823)
Donoso LA, Folberg R, Edelberg K, Arbizo V, Atkinson B, Herlyn M. Tissue distribution and
biochemical properties of an ocular melanoma-associated antigen. J Histochem Cytochem.
1985;33:1190-1196. PMID3905953
Folberg R, Donoso LA, Atkinson BF, Ernst CS, Herlyn M, Arbizo VV. An antimelanoma
monoclonal antibody and the histopathology of uveal melanomas. Arch Ophthalmol.
1985;103:275-279. PMID2579631
Herlyn M, Thurin J, Balaban G, Bennicelli JL, Herlyn D, Elder DE, Bondi E, Guerry D, Nowell P,
Clark WH, Koprowski H. Characteristics of cultured human melanocytes isolated from different
stages of tumor progression. Cancer Res. 1985;45:5670-5676. PMID4053039
Herlyn M, Blaszczyk M, Bennicelli J, Sears HF, Ernst CS, Ross AH, Koprowski H. Selection of
monoclonal antibodies detecting serodiagnostic human tumor markers. J Immunol Methods.
1985;80:107-116. PMID3859550
Herlyn M, Guerry D, Koprowski H. Recombinant gamma-interferon induces changes in expression
and shedding of antigens associated with normal human melanocytes, nevus cells, and primary
and metastatic melanoma cells. J Immunol. 1985;134:4226-4230. PMID2985706
Herlyn D, Herlyn M, Steplewski Z, Koprowski H. Monoclonal anti-human tumor antibodies of six
isotypes in cytotoxic reactions with human and murine effector cells. Cell Immunol. 1985;92:105114. PMID4075410
Herlyn D, Powe J, Ross AH, Herlyn M, Koprowski H. Inhibition of human tumor growth by IgG2A
monoclonal antibodies correlates with antibody density on tumor cells. J Immunol.
1985;134:1300-1304. PMID3965572
Herlyn M, Balaban G, Bennicelli J, Guerry DT, Halaban R, Herlyn D, Elder DE, Maul GG,
Steplewski Z, Nowell PC. Primary melanoma cells of the vertical growth phase: similarities to
metastatic cells. J Natl Cancer Inst. 1985;74:283-289. PMID3856042
10
Curriculum Vitae for Meenhard Herlyn, D.V.M., D.Sc.
65.
66.
67.
68.
69.
70.
71.
72.
73.
74.
75.
76.
77.
78.
79.
80.
81.
82.
83.
Koprowska I, Zipfel SA, Himes TR, Herlyn M. Common antigenic sites on exfoliated cells derived
from cervical carcinoma and in tumor cells of nonuterine origin as demonstrated by monoclonal
antibodies in immunoperoxidase assay. Cancer Res. 1985;45:5964-5968. PMID2414003
Koprowski H, Herlyn M, Balaban G, Parmiter A, Ross A, Nowell P. Expression of the receptor for
epidermal growth factor correlates with increased dosage of chromosome 7 in malignant
melanoma. Somat Cell Mol Genet. 1985;11:297-302. PMID2988138
Matera L, Francis MK, Herlyn M, Trucco M, Santoli D. Generation of natural killer-like activity in
mixed lymphocyte-tumor cell cultures. I. Role of HLA-DR antigens as stimulatory molecules. Nat
Immun Cell Growth Regul. 1985;4:90-102. PMID3160934
Sears HF, Shen JW, Herlyn M, Atkinson B, Engstrom PF, Koprowski H. Circulating tumor markers
and assessment of response to intrahepatic chemotherapy of colon carcinoma. Am J CIin Oncol.
1985;8:108-117. PMID2929709
Thurin J, Herlyn M, Hindsgaul O, Stromberg N, Karlsson KA, Elder D, Steplewski Z, Koprowski H.
Proton NMR and fast-atom bombardment mass spectrometry analysis of the melanomaassociated ganglioside 9-O-acetyl-GD3. J Biol Chem. 1985;260:14556-14563. PMID4055789
Balaban GB, Herlyn M, Clark WH Jr, Nowell PC. Karyotypic evolution in human malignant
melanoma. Cancer Genet Cytogenet. 1986;19:113-122. PMID3940171
Donoso LA, Felberg NT, Edelberg K, Borlinghaus P, Herlyn M. Metastatic uveal melanoma: an
ocular melanoma associated antigen in the serum of patients with metastatic disease. J
Immunoassay. 1986;7:273-283. PMID3805289
Ernst CS, Shen JW, Litwin S, Herlyn M, Koprowski H, Sears HF. Multiparameter evaluation of the
expression in situ of normal and tumor-associated antigens in human colorectal carcinoma. J Natl
Cancer Inst. 1986;77:387-395. PMID3461200
Ernst CS, Sears HF, Herlyn M, Herlyn D, Steplewski Z, Koprowski H. Detection of murine
immunoglobulin in human tissues following therapeutic infusion of monoclonal antibody.
Hybridoma. 1986;5(suppl 1):S79-86. PMID3527948
Ernst CS, Atkinson B, Chianese D, Peters J, Perry M, Herlyn M, Koprowski H. Differential
diagnosis between mesotheliomas and metastatic adenocarcinomas using monoclonal antibodies
against gastrointestinal carcinoma antigen and stage-specific embryonic antigen. Appl Pathol.
1986;4:115-124. PMID2885017
Herlyn D, Powe J, Munz DL, Alavi A, Herlyn M, Meinken GE, Srivastava SC, Koprowski H.
Radioimmunodetection of human tumor xenografts by monoclonal antibody F(ab’)2 fragments. Int
J Rad Appl Instrum B. 1986;13:401-405. PMID3793494
Koprowska I, Zipfel S, Ross AH, Herlyn M. Development of monoclonal antibodies that recognize
antigens associated with human cervical carcinoma. Acta Cytol. 1986;30:207-213. PMID3521172
Parmiter AH, Balaban G, Herlyn M, Clark WH Jr, Nowell PC. A t(1;19) chromosome translocation
in three cases of human malignant melanoma. Cancer Res. 1986;46:1526-1529. PMID3943110
Rakowicz-Szulczynska EM, Rodeck U, Herlyn M, Koprowski H. Chromatin binding of epidermal
growth factor, nerve growth factor, and platelet-derived growth factor in cells bearing the
appropriate surface receptors. Proc Natl Acad Sci U S A. 1986;83:3728-3732. PMID3012531
(PMC323596)
Steplewski Z, Herlyn D, Lubeck M, Kimoto Y, Herlyn M, Koprowski H. Mechanisms of tumor
growth inhibition. Hybridoma. 1986;5(suppl 1):S59-64. PMID3744386
Thurin J, Thurin M, Herlyn M, Elder DE, Steplewski Z, Clark WH Jr, Koprowski H. GD2
ganglioside biosynthesis is a distinct biochemical event in human melanoma tumor progression.
FEBS Lett. 1986;208:17-22. PMID3533633
Westermark B, Johnsson A, Paulsson Y, Betsholtz C, Heldin CH, Herlyn M, Rodeck U, Koprowski
H. Human melanoma cell lines of primary and metastatic origin express the genes encoding the
chains of platelet-derived growth factor (PDGF) and produce a PDGF-like growth factor. Proc Natl
Acad Sci U S A.1986;83:7197-7200. PMID3020539 (PMC386682)
Basu A, Murthy U, Rodeck U, Herlyn M, Mattes L, Das M. Presence of tumor-associated antigens
in epidermal growth factor receptors from different human carcinomas. Cancer Res.
1987;47:2531-2536. PMID2436750
Guerry DT, Herlyn MF, Elder DE, Herlyn MF. Interferon-gamma regulates the T cell response to
precursor nevi and biologically early melanoma. J Immunol. 1987;139:305-312. PMID3108402
11
Curriculum Vitae for Meenhard Herlyn, D.V.M., D.Sc.
84.
Herlyn M, Rodeck U, Mancianti M, Cardillo FM, Lang A, Ross AH, Jambrosic J, Koprowski H.
Expression of melanoma-associated antigens in rapidly dividing human melanocytes in culture.
Cancer Res. 1987;47:3057-3061. PMID3034401
85. Menssen HD, Herlyn M, Rodeck U, Koprowski H. Rapid dissociation of adherent human tumor
cells by ultrasound. J Immunol Methods. 1987;104:1-6. PMID3316390
86. Murthy U, Basu A, Rodeck U, Herlyn M, Ross AH, Das M. Binding of an antagonistic monoclonal
antibody to an intact and fragmented EGF-receptor polypeptide. Arch Biochem Biophys.
1987;252:549-560. PMID2434025
87. Ordonez NG, Freedman RS, Herlyn M. Lewis and related tumor-associated determinants on
ovarian carcinoma. Gynecol Oncol. 1987;26:1-10. PMID2431961
88. Rodeck U, Herlyn M, Koprowski H. Interactions between growth factor receptors and
corresponding monoclonal antibodies in human tumors. J Cell Biochem. 1987;35:315-320.
PMID2831241
89. Rodeck U, Herlyn M, Menssen HD, Furlanetto RW, Koprowski H. Metastatic but not primary
melanoma cell lines grow in vitro independently of exogenous growth factors. Int J Cancer.
1987;40:687-690. PMID3316051
90. Rodeck U, Herlyn M, Leander K, Borlinghaus P, Koprowski H. A mucin containing the X, Y, and H
type 2 carbohydrate determinants is shed by carcinoma cells. Hybridoma. 1987;6:389-401.
PMID2442094
91. Rodeck U, Herlyn M, Herlyn D, Molthoff C, Atkinson B, Varello M, Steplewski Z, Koprowski H.
Tumor growth modulation by a monoclonal antibody to the epidermal growth factor receptor:
immunologically mediated and effector cell-independent effects. Cancer Res. 1987;47:3692-3696.
PMID3297307
92. Thurin J, Thurin M, Kimoto Y, Herlyn M, Lubeck MD, Elder DE, Smereczynska M, Karlsson KA,
Clark WM Jr, Steplewski Z, Koprowski H. Monoclonal antibody-defined correlations in melanoma
between levels of GD2 and GD3 antigens and antibody-mediated cytotoxicity. Cancer Res.
1987;47:1229-1233. PMID3815333
93. Tsujisaki M, Igarashi M, Sakaguchi K, Eisinger M, Herlyn M, Ferrone S. Immunochemical and
functional analysis of HLA class II antigens induced by recombinant immune interferon on normal
epidermal melanocytes. J Immunol. 1987;138:1310-1316. PMID3100635
94. Herlyn M, Mancianti ML, Jambrosic J, Bolen JB, Koprowski H. Regulatory factors that determine
growth and phenotype of normal human melanocytes. Exp Cell Res. 1988;179:322-331.
PMID2461309
95. Linnenbach AJ, Huebner K, Reddy EP, Herlyn M, Parmiter AH, Nowell PC, Koprowski H.
Structural alteration in the MYB protooncogene and deletion within the gene encoding alpha-type
protein kinase C in human melanoma cell lines. Proc Natl Acad Sci U S A. 1988;85:74-78.
PMID2829178 (PMC279484)
96. Mancianti ML, Herlyn M, Weil D, Jambrosic J, Rodeck U, Becker D, Diamond L, Clark WH,
Koprowski H. Growth and phenotypic characteristics of human nevus cells in culture. J Invest
Dermatol.1988;90:134-141, 1988. PMID2828480
97. Rakowicz-Szulczynska EM, Herlyn M, Koprowski H. Nerve growth factor receptors in chromatin of
melanoma cells, proliferating melanocytes, and colorectal carcinoma cells in vitro. Cancer Res.
1988;48:7200-7206. PMID2461254
98. Williams NW, Rodeck U, Daly JM, Herlyn M. Growth regulatory factors for human colorectal
carcinoma cells in vitro. Surgical Forum. 1988;39:445-447.
99. Becker D, Meier CB, Herlyn M. Proliferation of human malignant melanomas is inhibited by
antisense oligodeoxynucleotides targeted against basic fibroblast growth factor. Embo J.
1989;8:3685-3691. PMID2684645 (PMC402051)
100. Berd D, Herlyn M, Koprowski H, Mastrangelo MJ. Flow cytometric determination of the frequency
and heterogeneity of expression of human melanoma-associated antigens. Cancer Res.
1989;49:6840-6844. PMID2582430
101. Elder DE, Rodeck U, Thurin J, Cardillo F, Clark WH, Stewart R, Herlyn M. Antigenic profile of
tumor progression stages in human melanocytic nevi and melanomas. Cancer Res.
1989;49:5091-5096. PMID2548711
12
Curriculum Vitae for Meenhard Herlyn, D.V.M., D.Sc.
102. Iliopoulos D, Ernst CS, Steplewski Z, Jambrosic JA, Rodeck U, Herlyn M, Clark WH Jr, Koprowski
H, Herlyn D. Inhibition of metastases of a human melanoma xenograft by monoclonal antibody to
the GD2/GD3 gangliosides. J Natl Cancer Inst. 1989;81:440-444. PMID2918552
103. Jambrosic J, Mancianti ML, Ricciardi R, Sela BA, Koprowski H, Herlyn M. Transformation of
normal human melanocytes and non-malignant nevus cells by adenovirus 12-SV40 hybrid virus.
Int J Cancer. 1989;44:1117-1123. PMID2558080
104. Kraemer KH, Herlyn M, Yuspa SH, Clark WH Jr, Townsend GK, Neises GR, Hearing VJ.
Reduced DNA repair in cultured melanocytes and nevus cells from a patient with xeroderma
pigmentosum. Arch Dermatol. 125:263-268, 1989. PMID2913963
105. Strom BL, Iliopoulos D, Atkinson B, Herlyn M, West SL, Maislin G, Saul S, Varello MA, RodriguezMartinez HA, Rios-Dalenz J. Pathophysiology of tumor progression in human gallbladder: flow
cytometry, CEA, and CA 19-9 levels in bile and serum in different stages of gallbladder disease. J
Natl Cancer Inst. 1989;81:1575-1580. PMID2795683
106. Wolf BC, Salem RR, Sears HF, Horst DA, Lavin PT, Herlyn M, Itzkowitz SH, Schlom J, Steele GD
Jr. The expression of colorectal carcinoma-associated antigens in the normal colonic mucosa. An
immunohistochemical analysis of regional distribution. Am J Pathol. 1989;135:111-119.
PMID2476033 (PMC1880239)
107. Albelda SM, Mette SA, Elder DE, Stewart R, Damjanovich L, Herlyn M, Buck CA. Integrin
distribution in malignant melanoma: association of the beta 3 subunit with tumor progression.
Cancer Res. 1990;50:6757-6764. PMID2208139
108. Becker D, Beebe SJ, Herlyn M. Differential expression of protein kinase C and cAMP-dependent
protein kinase in normal human melanocytes and malignant melanomas. Oncogene.
1990;5:1133-1139. PMID2392322
109. Dion AS, Williams CJ, Herlyn M, Major P. Human milk fat globule membrane glycoproteins
express blood group-related determinants primarily on mucin-like epithelial membrane antigens
and gp70. Biochem Int. 1990;22:295-302. PMID1708665
110. Howe CC, Kath R, Mancianti ML, Herlyn M, Mueller S, Cristofalo V. Expression and structure of
human SPARC transcripts: SPARC mRNA is expressed by human cells involved in extracellular
matrix production and some of these cells show an unusual expression pattern. Exp Cell Res.
1990;188:185-191. PMID2335186
111. Kath R, Rodeck U, Parmiter A, Jambrosic J, Herlyn M. Growth factor independence in vitro of
primary melanoma cells from advanced but not early or intermediate lesions. Cancer Therapy and
Control. 1990;1:179-191.
112. Mancianti ML, Clark WH, Hayes FA, Herlyn M. Malignant melanoma simulants arising in
congenital melanocytic nevi do not show experimental evidence for a malignant phenotype. Am J
Pathol.1990;136:817-829. PMID2327470 (PMC1877645)
113. Manni A, Wright C, Badger B, Bartholomew M, Herlyn M, Mendelsohn J, Masui H, Demers L.
Role of transforming growth factor-alpha-related peptides in the autocrine/paracrine control of
experimental breast cancer growth in vitro by estradiol, prolactin, and progesterone. Breast
Cancer Res Treat. 1990;15:73-83. PMID2322651
114. Rodeck U, Williams N, Murthy U, Herlyn M. Monoclonal antibody 425 inhibits growth stimulation of
carcinoma cells by exogenous EGF and tumor-derived EGF/TGF-alpha. J Cell Biochem.
1990;44:69-79. PMID2250044
115. Singletary SE, Williams NN, Rodeck U, Larry L, Tucker S, Spitzer G, Herlyn M. Transforming
growth factor-alpha secretion by epidermal growth factor-dependent human tumor cell lines.
Anticancer Res. 1990;10:1501-1505. PMID2285223
116. Strom BL, Maislin G, West SL, Atkinson B, Herlyn M, Saul S, Rodriguez-Martinez HA, RiosDalenz J, Iliopoulos D, Soloway RD. Serum CEA and CA 19-9: potential future diagnostic or
screening tests for gallbladder cancer? Int J Cancer. 1990;45:821-824. PMID2335386
117. Valyi-Nagy IT, Murphy GF, Mancianti ML, Whitaker D, Herlyn M. Phenotypes and interactions of
human melanocytes and keratinocytes in an epidermal reconstruction model. Lab Invest.
1990;62:314-324. PMID2179623
118. Bröcker EB, Magiera H, Herlyn M. Nerve growth and expression of receptors for nerve growth
factor in tumors of melanocyte origin. J Invest Dermatol.1991;96:662-665. PMID1850772
13
Curriculum Vitae for Meenhard Herlyn, D.V.M., D.Sc.
119. Cornil I, Theodorescu D, Man S, Herlyn M, Jambrosic J, Kerbel RS. Fibroblast cell interactions
with human melanoma cells affect tumor cell growth as a function of tumor progression. Proc Natl
Acad Sci U S A. 1991;88:6028-6032. PMID2068080 (PMC52015)
120. Herlyn M, Graeven U, Speicher D, Sela BA, Bennicelli JL, Kath R, Guerry DT. Characterization of
tenascin secreted by human melanoma cells. Cancer Res. 1991;51:4853-4858. PMID1716515
121. Kath R, Jambrosic JA, Holland L, Rodeck U, Herlyn M. Development of invasive and growth
factor-independent cell variants from primary human melanomas. Cancer Res. 1991;51:22052211. PMID2009539
122. Radrizzani M, Benedetti B, Castelli C, Longo A, Ferrara GB, Herlyn M, Parmiani G, Fossati G.
Human allogeneic melanoma-reactive T-helper lymphocyte clones: functional analysis of
lymphocyte-melanoma interactions. Int J Cancer. 1991;49:823-830. PMID1835714
123. Rodeck U, Melber K, Kath R, Menssen HD, Varello M, Atkinson B, Herlyn M. Constitutive
expression of multiple growth factor genes by melanoma cells but not normal melanocytes. J
Invest Dermatol. 1991;97:20-26. PMID2056188
124. Becker D, Lee PL, Rodeck U, Herlyn M. Inhibition of the fibroblast growth factor receptor 1
(FGFR-1) gene in human melanocytes and malignant melanomas leads to inhibition of
proliferation and signs indicative of differentiation. Oncogene. 1992;7:2303-2313. PMID1437152
125. Ura Y, Dion AS, Williams CJ, Olsen BD, Redfield ES, Ishida M, Herlyn M, Major PP. Quantitative
dot blot analyses of blood-group-related antigens in paired normal and malignant human breast
tissues. Int J Cancer. 1992;50:57-63. PMID1728614
126. Williams NN, Györfi T, Iliopoulos D, Herlyn D, Greenstein D, Linnenbach AJ, Daly JM, Jensen P,
Rodeck U, Herlyn M. Growth-factor-independence and invasive properties of colorectal carcinoma
cells. Int J Cancer. 1992;50:274-280. PMID1730521
127. Anichini A, Maccalli C, Mortarini R, Salvi S, Mazzocchi A, Squarcina P, Herlyn M, Parmiani G.
Melanoma cells and normal melanocytes share antigens recognized by HLA-A2-restricted
cytotoxic T cell clones from melanoma patients. J Exp Med. 1993;177:989-998. PMID8459226
128. Easty DJ, Ganz SE, Farr CJ, Lai C, Herlyn M, Bennett DC. Novel and known protein tyrosine
kinases and their abnormal expression in human melanoma. J Invest Dermatol. 1993;101:679684. PMID8228328
129. Forsberg K, Valyi-Nagy I, Heldin CH, Herlyn M, Westermark B. Platelet-derived growth factor
(PDGF) in oncogenesis: development of a vascular connective tissue stroma in xenotransplanted
human melanoma producing PDGF-BB. Proc Natl Acad Sci U S A. 1993;90:393-397.
PMID8380638 (PMC45668)
130. Iliopoulos D, Atkinson B, Saul SH, Herlyn M, Rodriguez-Martinez HA, West SL, Maislin G,
Soloway RD, Strom BL. Differences in antigen expression between neoplastic and nonneoplastic
gallbladder epithelium: an immunohistochemical study. Dig Dis Sci. 1993;38:155-160.
PMID8420749
131. Juhasz I, Lazarus GS, Murphy GF, Shih IM, Herlyn M. Development of pemphigus vulgaris-like
lesions in severe combined immunodeficiency disease mice reconstituted with lymphocytes from
patients. J Clin Invest. 1993;92:2401-2407. PMID8227357 (PMC288423)
132. Juhasz I, Murphy GF, Yan HC, Herlyn M, Albelda SM. Regulation of extracellular matrix proteins
and integrin cell substratum adhesion receptors on epithelium during cutaneous human wound
healing in vivo. Am J Pathol. 1993;143:1458-1469. PMID7694470 (PMC1887182)
133. Juhasz I, Albelda SM, Elder DE, Murphy GF, Adachi K, Herlyn D, Valyi-Nagy IT, Herlyn M.
Growth and invasion of human melanomas in human skin grafted to immunodeficient mice. Am J
Pathol. 1993;143:528-537. PMID8342600 (PMC1887031)
134. Lazzaro B, Elder DE, Rebers A, Power L, Herlyn M, Menrad A, Johnson B. Immunophenotyping
of compound and spitz nevi and vertical growth-phase melanomas using a panel of monoclonal
antibodies reactive in paraffin sections. J Invest Dermatol.1993;100:313S-317S. PMID8440911
135. Mancianti ML, Györfi T, Shih IM, Valyi-Nagy I, Levengood G, Menssen HD, Halpern AC, Elder
DE, Herlyn M. Growth regulation of cultured human nevus cells. J Invest Dermatol.
1993;100:281S-287S. PMID8440904
136. Menrad A, Speicher D, Wacker J, Herlyn M. Biochemical and functional characterization of
aminopeptidase N expressed by human melanoma cells. Cancer Res. 1993;53:1450-1455.
PMID8095183
14
Curriculum Vitae for Meenhard Herlyn, D.V.M., D.Sc.
137. Salem RR, Wolf BC, Sears HF, Lavin PT, Ravikumar TS, DeCoste D, D’Emilia JC, Herlyn M,
Schlom J, Gottlieb LS, Steele DG. Expression of colorectal carcinoma-associated antigens in
colonic polyps. J Surg Res. 1993;55:249-255. PMID8412106
138. Sensi M, Salvi S, Castelli C, Maccalli C, Mazzocchi A, Mortarini R, Nicolini G, Herlyn M, Parmiani
G, Anichini A. T cell receptor (TCR) structure of autologous melanoma-reactive cytotoxic T
lymphocyte (CTL) clones: tumor-infiltrating lymphocytes overexpress in vivo the TCR beta chain
sequence used by an HLA-A2-restricted and melanocyte-lineage-specific CTL clone. J Exp Med.
1993;178:1231-1246. PMID8376931
139. Valyi-Nagy IT, Hirka G, Jensen PJ, Shih IM, Juhasz I, Herlyn M. Undifferentiated keratinocytes
control growth, morphology, and antigen expression of normal melanocytes through cell-cell
contact. Lab Invest. 1993;69:152-159. PMID8350597
140. Valyi-Nagy I, Shih IM, Györfi T, Greenstein D, Juhasz I, Elder DE, Herlyn M. Spontaneous and
induced differentiation of human melanoma cells. Int J Cancer. 1993;54:159-165. PMID8478142
141. Weiss J, Schwechheimer K, Cavenee WK, Herlyn M, Arden KC. Mutation and expression of the
p53 gene in malignant melanoma cell lines. Int J Cancer. 1993;54:693-699. PMID8514460
142. Yan HC, Juhasz I, Pilewski J, Murphy GF, Herlyn M, Albelda SM. Human/severe combined
immunodeficient mouse chimeras: an experimental in vivo model system to study the regulation of
human endothelial cell-leukocyte adhesion molecules. J Clin Invest. 1993;91:986-996.
PMID7680673 (PMC288051)
143. Gratas C, Herlyn M, Becker D. Isolation and analysis of novel human melanocyte-specific cDNA
clones. DNA Cell Biol. 1994;13:515-519. PMID8024694
144. Hijiya N, Zhang J, Ratajczak MZ, Kant JA, DeRiel K, Herlyn M, Zon G, Gewirtz AM. Biologic and
therapeutic significance of MYB expression in human melanoma. Proc Natl Acad Sci U S A.
1994;91:4499-4503. PMID8183937 (PMC43813)
145. Marincola FM, Shamamian P, Alexander RB, Gnarra JR, Turetskaya RL, Nedospasov SA,
Simonis TB, Taubenberger JK, Yannelli J, Mixon A, Restifo NP, Herlyn M, Rosenberg SA. Loss of
HLA haplotype and B locus down-regulation in melanoma cell lines. J Immunol. 1994;153:12251237. PMID8027550
146. Mattei S, Colombo MP, Melani C, Silvani A, Parmiani G, Herlyn M. Expression of cytokine/growth
factors and their receptors in human melanoma and melanocytes. Int J Cancer. 1994;56:853-857.
PMID7509778
147. Quong RY, Bickford ST, Ing YL, Terman B, Herlyn M, Lassam NJ. Protein kinases in normal and
transformed melanocytes. Melanoma Res. 1994;4:313-319. PMID7858416
148. Shih IM, Elder DE, Hsu M-Y, Herlyn M. Regulation of Mel-CAM/MUC18 expression on
melanocytes of different stages of tumor progression by normal keratinocytes. Am J Pathol.
1994;145:837-845. PMID7943174 (PMC1887332)
149. Shih IM, Elder DE, Speicher D, Johnson JP, Herlyn M. Isolation and functional characterization of
the A32 melanoma-associated antigen. Cancer Res. 1994;54:2514-2520. PMID8162602
150. Weber J, Salgaller M, Samid D, Johnson B, Herlyn M, Lassam N, Treisman J, Rosenberg SA.
Expression of the MAGE-1 tumor antigen is up-regulated by the demethylating agent 5-aza-2’deoxycytidine. Cancer Res. 1994;54:1766-1771. PMID7511051
151. Easty DJ, Guthrie BA, Maung K, Farr CJ, Lindberg RA, Toso RJ, Herlyn M, Bennett DC. Protein
B61 as a new growth factor: expression of B61 and up-regulation of its receptor epithelial cell
kinase during melanoma progression. Cancer Res. 1995;55:2528-2532. PMID7780963
152. Easty DJ, Herlyn M, Bennett DC. Abnormal protein tyrosine kinase gene expression during
melanoma progression and metastasis. Int J Cancer. 1995;60:129-136. PMID7814145
153. Jiang H, Lin J, Su ZZ, Herlyn M, Kerbel RS, Weissman BE, Welch DR, Fisher PB. The melanoma
differentiation-associated gene mda-6, which encodes the cyclin-dependent kinase inhibitor p21,
is differentially expressed during growth, differentiation and progression in human melanoma
cells. Oncogene. 1995;10:1855-1864. PMID7753561
154. Mortarini R, Gismondi A, Maggioni A, Santoni A, Herlyn M, Anichini A. Mitogenic activity of laminin
on human melanoma and melanocytes: different signal requirements and role of beta 1 integrins.
Cancer Res. 1995;55:4702-4710. PMID7553652
155. Soballe PW, Maloy WL, Myrga ML, Jacob LS, Herlyn M. Experimental local therapy of human
melanoma with lytic magainin peptides. Int J Cancer. 1995;60:280-284. PMID7829229
15
Curriculum Vitae for Meenhard Herlyn, D.V.M., D.Sc.
156. Hsu M-Y, Wheelock MJ, Johnson KR, Herlyn M. Shifts in cadherin profiles between human
normal melanocytes and melanomas. J Investig Dermatol Symp Proc. 1996;1:188-194.
PMID9627715
157. Juhasz I, Simon M Jr, Herlyn M, Hunyadi J. Repopulation of Langerhans cells during wound
healing in an experimental human skin/SCID mouse model. Immunol Lett. 1996;52:125-128.
PMID8905406
158. Marincola FM, Hijazi YM, Fetsch P, Salgaller ML, Rivoltini L, Cormier J, Simonis TB, Duray PH,
Herlyn M, Kawakami Y, Rosenberg SA. Analysis of expression of the melanoma-associated
antigens MART-1 and gp100 in metastatic melanoma cell lines and in in situ lesions. J
Immunother Emphasis Tumor Immunol. 1996;19:192-205. PMID8811494
159. Simon M Jr, Juhasz I, Herlyn M, Hunyadi J. Thrombospondin receptor (CD36) expression of
human keratinocytes during wound healing in a SCID mouse/human skin repair model. J
Dermatol. 1996;23:305-309. PMID9675818
160. Soballe PW, Montone KT, Satyamoorthy K, Nesbit M, Herlyn M. Carcinogenesis in human skin
grafted to SCID mice. Cancer Res. 1996;56:757-764. PMID8631010
161. Andalib AR, Lawry J, Ali SA, Murray AK, Sisley K, Silcocks P, Herlyn M, Rees RC. Cytokine
modulation of antigen expression in human melanoma cell lines derived from primary and
metastatic tumour tissues. Melanoma Res. 1997;7:32-42. PMID9067963
162. Atillasoy ES, Elenitsas R, Sauter ER, Soballe PW, Herlyn M. UVB induction of epithelial tumors in
human skin using a RAG-1 mouse xenograft model. J Invest Dermatol.1997;109:704-709.
PMID9406808
163. Satyamoorthy K, DeJesus E, Linnenbach AJ, Kraj B, Kornreich DL, Rendle S, Elder DE, Herlyn
M. Melanoma cell lines from different stages of progression and their biological and molecular
analyses. Melanoma Res. 1997;7(suppl 2):S35-42. PMID9578514
164. Satyamoorthy K, Soballe PW, Soans F, Herlyn M. Adenovirus infection enhances killing of
melanoma cells by a mitotoxin. Cancer Res. 1997;57:1873-1876. PMID9157978
165. Shih IM, Speicher D, Hsu M-Y, Levine E, Herlyn M. Melanoma cell-cell interactions are mediated
through heterophilic Mel-CAM/ligand adhesion. Cancer Res. 1997;57:3835-3840. PMID9288796
(PMC1857834)
166. Shih IM, Hsu M-Y, Palazzo JP, Herlyn M. The cell-cell adhesion receptor Mel-CAM acts as a
tumor suppressor in breast carcinoma. Am J Pathol. 1997;151:745-751. PMID9284823
167. Wechsler-Reya R, Elliott K, Herlyn M, Prendergast GC. The putative tumor suppressor BIN1 is a
short-lived nuclear phosphoprotein, the localization of which is altered in malignant cells. Cancer
Res. 1997;57:3258-3263. PMID9242458
168. Atillasoy ES, Seykora JT, Soballe PW, Elenitsas R, Nesbit M, Elder DE, Montone KT, Sauter E,
Herlyn M. UVB induces atypical melanocytic lesions and melanoma in human skin. Am J Pathol.
1998;152:1179-1186. PMID9588887 (PMC1858575)
169. Cass DL, Bullard KM, Sylvester KG, Yang EY, Sheppard D, Herlyn M, Adzick NS. Epidermal
integrin expression is upregulated rapidly in human fetal wound repair. J Pediatr Surg.
1998;33:312-316. PMID9498408
170. Hsu M-Y, Shih DT, Meier FE, Van Belle P, Hsu JY, Elder DE, Buck CA, Herlyn M. Adenoviral
gene transfer of beta3 integrin subunit induces conversion from radial to vertical growth phase in
primary human melanoma. Am J Pathol. 1998;153:1435-1442. PMID9811334 (PMC1853416)
171. Maul GG, Jensen DE, Ishov AM, Herlyn M, Rauscher FJ 3rd. Nuclear redistribution of BRCA1
during viral infection. Cell Growth Differ. 1998;9:743-755. PMID9751118
172. Prabhu NS, Somasundaram K, Satyamoorthy K, Herlyn M, El-Deiry WS. p73beta, unlike p53,
suppresses growth and induces apoptosis of human papillomavirus E6-expressing cancer cells.
Int J Oncol. 1998;13:5-9. PMID9625796
173. Rauscher FJ 3rd, Morris JF, Fredericks WJ, Lopez-Guisa J, Balakrishnan C, Jost M, Herlyn M,
Rodeck U. Characterization of monoclonal antibodies directed to the amino-terminus of the WT1,
Wilms’ tumor suppressor protein. Hybridoma. 1998;17:191-198. PMID9627060
174. Ronai Z, Yang YM, Fuchs SY, Adler V, Sardana M, Herlyn M. ATF2 confers radiation resistance
to human melanoma cells. Oncogene. 1998;16:523-531. PMID9484842
16
Curriculum Vitae for Meenhard Herlyn, D.V.M., D.Sc.
175. Sauter ER, Klein-Szanto AJ, Atillasoy E, Montone KT, Goodrow T, Binder RL, Seykora JT, Herlyn
M. Ultraviolet B-induced squamous epithelial and melanocytic cell changes in a xenograft model
of cancer development in human skin. Mol Carcinog. 1998;23:168-174. PMID9833777
176. Shih IM, Nesbit M, Herlyn M, Kurman RJ. A new Mel-CAM (CD146)-specific monoclonal antibody,
MN-4, on paraffin-embedded tissue. Mod Pathol. 1998;11:1098-1106. PMID9831208
177. Easty DJ, Hill SP, Hsu M-Y, Fallowfield ME, Florenes VA, Herlyn M, Bennett DC. Up-regulation of
ephrin-A1 during melanoma progression. Int J Cancer. 1999;84:494-501. PMID10502726
178. Ge K, DuHadaway J, Du W, Herlyn M, Rodeck U, Prendergast GC. Mechanism for elimination of
a tumor suppressor: aberrant splicing of a brain-specific exon causes loss of function of Bin1 in
melanoma. Proc Natl Acad Sci U S A. 1999;96:9689-9694. PMID10449755 (PMC22271)
179. Hsu JY, Hsu M-Y, Sorger T, Herlyn M, Levine EM. Heparin/endothelial cell growth supplement
regulates matrix gene expression and prolongs life span of vascular smooth muscle cells through
modulation of interleukin-1. In Vitro Cell Dev Biol Anim. 1999;35:647-654. PMID10614876
180. Krasilnikov M, Adler V, Fuchs SY, Dong Z, Haimovitz-Friedman A, Herlyn M, Ronai Z.
Contribution of phosphatidylinositol 3-kinase to radiation resistance in human melanoma cells.
Mol Carcinog. 1999;24:64-69. PMID10029412
181. Liechty KW, Nesbit M, Herlyn M, Radu A, Adzick NS, Crombleholme TM. Adenoviral-mediated
overexpression of platelet-derived growth factor-B corrects ischemic impaired wound healing. J
Invest Dermatol. 1999;113:375-383. PMID10469337
182. Mitra J, Dai CY, Somasundaram K, El-Deiry WS, Satyamoorthy K, Herlyn M, Enders GH.
Induction of p21(WAF1/CIP1) and inhibition of Cdk2 mediated by the tumor suppressor
p16(INK4a). Mol Cell Biol. 1999;19:3916-3928. PMID10207115 (PMC84249)
183. Moretti S, Pinzi C, Spallanzani A, Berti E, Chiarugi A, Mazzoli S, Fabiani M, Vallecchi C, Herlyn
M. Immunohistochemical evidence of cytokine networks during progression of human melanocytic
lesions. Int J Cancer. 1999;84:160-168. PMID10096249
184. Nesbit M, Nesbit HK, Bennett J, Andl T, Hsu M-Y, DeJesus E, McBrian M, Gupta AR, Eck SL,
Herlyn M. Basic fibroblast growth factor induces a transformed phenotype in normal human
melanocytes. Oncogene. 1999;18:6469-6476. PMID10597249
185. Prabhu NS, Somasundaram K, Tian H, Enders GH, Satyamoorthy K, Herlyn M, El-Deiry WS. The
administration schedule of cyclin-dependent kinase inhibitor gene therapy and etoposide
chemotherapy is a major determinant of cytotoxicity. Int J Oncol. 1999;15:209-216.
PMID10402229
186. Sauter ER, Nesbit M, Litwin S, Klein-Szanto AJ, Cheffetz S, Herlyn M. Antisense cyclin D1
induces apoptosis and tumor shrinkage in human squamous carcinomas. Cancer Res.
1999;59:4876-4881. PMID10519399
187. Sauter ER, Nesbit M, Watson JC, Klein-Szanto A, Litwin S, Herlyn M. Vascular endothelial growth
factor is a marker of tumor invasion and metastasis in squamous cell carcinomas of the head and
neck. Clin Cancer Res. 1999;5:775-782. PMID10213212
188. Van Belle PA, Elenitsas R, Satyamoorthy K, Wolfe JT, Guerry DT, Schuchter L, Van Belle TJ,
Albelda S, Tahin P, Herlyn M, Elder DE. Progression-related expression of beta3 integrin in
melanomas and nevi. Hum Pathol. 1999;30:562-567. PMID10333228
189. Ayyanathan K, Fredericks WJ, Berking C, Herlyn M, Balakrishnan C, Gunther E, Rauscher FJ 3rd.
Hormone-dependent tumor regression in vivo by an inducible transcriptional repressor directed at
the PAX3-FKHR oncogene. Cancer Res. 2000;60:5803-5814. PMID11059777
190. Chandler LA, Doukas J, Gonzalez AM, Hoganson DK, Gu DL, Ma C, Nesbit M, Crombleholme
TM, Herlyn M, Sosnowski BA, Pierce GF. FGF2-Targeted adenovirus encoding platelet-derived
growth factor-B enhances de novo tissue formation. Mol Ther. 2000;2:153-160. PMID10947943
191. Fredericks WJ, Ayyanathan K, Herlyn M, Friedman JR, Rauscher FJ 3rd. An engineered PAX3KRAB transcriptional repressor inhibits the malignant phenotype of alveolar rhabdomyosarcoma
cells harboring the endogenous PAX3-FKHR oncogene. Mol Cell Biol. 2000;20:5019-5031.
PMID10866659 (PMC85952)
192. Hsu M-Y, Meier FE, Nesbit M, Hsu JY, Van Belle P, Elder DE, Herlyn M. E-cadherin expression in
melanoma cells restores keratinocyte-mediated growth control and down-regulates expression of
invasion-related adhesion receptors. Am J Pathol. 2000;156:1515-1525. PMID10793063
(PMC1876923)
17
Curriculum Vitae for Meenhard Herlyn, D.V.M., D.Sc.
193. Hsu M, Andl T, Li G, Meinkoth JL, Herlyn M. Cadherin repertoire determines partner-specific gap
junctional communication during melanoma progression. J Cell Sci. 2000;113(Pt 9):1535-1542.
PMID10751145
194. Margolis DJ, Crombleholme T, Herlyn M. Clinical protocol: phase I trial to evaluate the safety of
H5.020CMV.PDGF-B for the treatment of a diabetic insensate foot ulcer. Wound Repair Regen.
2000;8:480-493. PMID11208175
195. Meier F, Nesbit M, Hsu M-Y, Martin B, Van Belle P, Elder DE, Schaumburg-Lever G, Garbe C,
Walz TM, Donatien P, Crombleholme TM, Herlyn M. Human melanoma progression in skin
reconstructs : biological significance of bFGF. Am J Pathol. 2000;156:193-200. PMID10623667
(PMC1868639)
196. Oka M, Berking C, Nesbit M, Satyamoorthy K, Schaider H, Murphy G, Ichihashi M, Sauter E,
Herlyn M. Interleukin-8 overexpression is present in pyoderma gangrenosum ulcers and leads to
ulcer formation in human skin xenografts. Lab Invest. 2000;80:595-604. PMID10780675
197. Satyamoorthy K, Oka M, Herlyn M. An antisense strategy for inhibition of human melanoma
growth targets the growth factor pleiotrophin. Pigment Cell Res. 2000;13(suppl 8):87-93.
PMID11041363
198. Satyamoorthy K, Chehab NH, Waterman MJ, Lien MC, El-Deiry WS, Herlyn M, Halazonetis TD.
Aberrant regulation and function of wild-type p53 in radioresistant melanoma cells. Cell Growth
Differ. 2000;11:467-474. PMID11007451
199. Sauter ER, Herlyn M, Liu SC, Litwin S, Ridge JA. Prolonged response to antisense cyclin D1 in a
human squamous cancer xenograft model. Clin Cancer Res. 2000;6:654-660. PMID10690551
200. Smedley D, Sidhar S, Birdsall S, Bennett D, Herlyn M, Cooper C, Shipley J. Characterization of
chromosome 1 abnormalities in malignant melanomas. Genes Chromosomes Cancer.
2000;28:121-125. PMID10738310
201. St John LS, Sauter ER, Herlyn M, Litwin S, Adler-Storthz K. Endogenous p53 gene status predicts
the response of human squamous cell carcinomas to wild-type p53. Cancer Gene Ther.
2000;7:749-756. PMID10830722
202. Sylvester KG, Nesbit M, Radu A, Herlyn M, Adzick NS, Crombleholme TM. Adenoviral-mediated
gene transfer in wound healing: acute inflammatory response in human skin in the SCID mouse
model. Wound Repair Regen. 2000;8:36-44. PMID10760213
203. Berking C, Takemoto R, Schaider H, Showe L, Satyamoorthy K, Robbins P, Herlyn M.
Transforming growth factor-beta1 increases survival of human melanoma through stroma
remodeling. Cancer Res. 2001;61:8306-8316. PMID11719464
204. Berking C, Takemoto R, Satyamoorthy K, Elenitsas R, Herlyn M. Basic fibroblast growth factor
and ultraviolet B transform melanocytes in human skin. Am J Pathol. 2001;158:943-953.
PMID11238042 (PMC1850339)
205. Doukas J, Chandler LA, Gonzalez AM, Gu D, Hoganson DK, Ma C, Nguyen T, Printz MA, Nesbit
M, Herlyn M, Crombleholme TM, Aukerman SL, Sosnowski BA, Pierce GF. Matrix immobilization
enhances the tissue repair activity of growth factor gene therapy vectors. Hum Gene Ther.
2001;12:783-798. PMID11339895
206. Herlyn M, Ferrone S, Ronai Z, Finerty J, Pelroy R, Mohla S. Melanoma biology and progression.
Cancer Res. 2001;61:4642-4643. PMID11389102
207. Iida J, Pei D, Kang T, Simpson MA, Herlyn M, Furcht LT, McCarthy JB. Melanoma chondroitin
sulfate proteoglycan regulates matrix metalloproteinase-dependent human melanoma invasion
into type I collagen. J Biol Chem. 2001;276:18786-18794. PMID11278606
208. Li G, Schaider H, Satyamoorthy K, Hanakawa Y, Hashimoto K, Herlyn M. Downregulation of Ecadherin and desmoglein 1 by autocrine hepatocyte growth factor during melanoma development.
Oncogene. 2001;20:8125-8135. PMID11781826
209. Li G, Satyamoorthy K, Herlyn M. N-cadherin-mediated intercellular interactions promote survival
and migration of melanoma cells. Cancer Res. 2001;61:3819-3825. PMID11325858
210. McArdle L, Rafferty M, Maelandsmo GM, Bergin O, Farr CJ, Dervan PA, O’Loughlin S, Herlyn M,
Easty DJ. Protein tyrosine phosphatase genes downregulated in melanoma. J Invest Dermatol.
2001;117:1255-1260. PMID11710941
211. Nesbit M, Schaider H, Berking C, Shih DT, Hsu M-Y, McBrian M, Crombleholme TM, Elenitsas R,
Buck C, Herlyn M. Alpha5 and alpha2 integrin gene transfers mimic the PDGF-B-induced
18
Curriculum Vitae for Meenhard Herlyn, D.V.M., D.Sc.
212.
213.
214.
215.
216.
217.
218.
219.
220.
221.
222.
223.
224.
225.
226.
227.
228.
transformed phenotype of fibroblasts in human skin. Lab Invest. 2001;81:1263-1274.
PMID11555674
Nesbit M, Schaider H, Miller TH, Herlyn M. Low-level monocyte chemoattractant protein-1
stimulation of monocytes leads to tumor formation in nontumorigenic melanoma cells. J Immunol.
2001;166:6483-6490. PMID11359798
Satyamoorthy K, Li G, Vaidya B, Patel D, Herlyn M. Insulin-like growth factor-1 induces survival
and growth of biologically early melanoma cells through both the mitogen-activated protein kinase
and beta-catenin pathways. Cancer Res. 2001;61:7318-7324. PMID11585772
Satyamoorthy K, Muyrers J, Meier F, Patel D, Herlyn M. Mel-CAM-specific genetic suppressor
elements inhibit melanoma growth and invasion through loss of gap junctional communication.
Oncogene. 2001;20:4676-4684. PMID11498790
Sauter ER, Nesbit M, Tichansky D, Liu ZJ, Shirakawa T, Palazzo J, Herlyn M. Fibroblast growth
factor-binding protein expression changes with disease progression in clinical and experimental
human squamous epithelium. Int J Cancer. 2001;92:374-381. PMID11291074
Sauter ER, Tichansky D, Furth EE, Herlyn M. Tumor-associated antigen expression and growth
requirements predict tumorigenesis in squamous cell carcinoma. In Vitro Cell Dev Biol Anim.
2001;37:530-535. PMID11669287
Berking C, Takemoto R, Binder RL, Hartman SM, Ruiter DJ, Gallagher PM, Lessin SR, Herlyn M.
Photocarcinogenesis in human adult skin grafts. Carcinogenesis. 2002;23:181-187.
PMID11756239
Brose MS, Volpe P, Feldman M, Kumar M, Rishi I, Gerrero R, Einhorn E, Herlyn M, Minna J,
Nicholson A, Roth JA, Albelda SM, Davies H, Cox C, Brignell G, Stephens P, Futreal PA, Wooster
R, Stratton MR, Weber BL. BRAF and RAS mutations in human lung cancer and melanoma.
Cancer Res. 2002;62:6997-7000. PMID12460918
Samadi DS, Jacobs IN, Walsh D, Bouchard S, Herlyn M, Crombleholme TM. Adenovirusmediated ex vivo gene transfer of human vascular endothelial growth factor in a rabbit
laryngotracheal reconstruction model. Ann Otol Rhinol Laryngol. 2002;111:295-301.
PMID11991579
Satyamoorthy K, Li G, Van Belle PA, Elder DE, Herlyn M. A versatile method for the removal of
melanin from ribonucleic acids in melanocytic cells. Melanoma Res. 2002;12:449-452.
PMID12394186
Satyamoorthy K, Li G, Vaidya B, Kalabis J, Herlyn M. Insulin-like growth factor-I-induced
migration of melanoma cells is mediated by interleukin-8 induction. Cell Growth Differ.
2002;13:87-93. PMID11864912
Sauter ER, Takemoto R, Litwin S, Herlyn M. p53 alone or in combination with antisense cyclin D1
induces apoptosis and reduces tumor size in human melanoma. Cancer Gene Ther. 2002;9:807812. PMID12224020
Sauter ER, Yeo UC, von Stemm A, Zhu W, Litwin S, Tichansky DS, Pistritto G, Nesbit M, Pinkel
D, Herlyn M, Bastian BC. Cyclin D1 is a candidate oncogene in cutaneous melanoma. Cancer
Res. 2002;62:3200-3206. PMID12036934
Shih IM, Hsu M-Y, Oldt RJ 3rd, Herlyn M, Gearhart JD, Kurman RJ. The role of E-cadherin in the
motility and invasion of implantation site intermediate trophoblast. Placenta. 2002;23:706-715.
PMID12398810
Sturm RA, Satyamoorthy K, Meier F, Gardiner BB, Smit DJ, Vaidya B, Herlyn M.
Osteonectin/SPARC induction by ectopic beta(3) integrin in human radial growth phase primary
melanoma cells. Cancer Res. 2002;62:226-232. PMID11782382
Velazquez OC, Snyder R, Liu ZJ, Fairman RM, Herlyn M. Fibroblast-dependent differentiation of
human microvascular endothelial cells into capillary-like 3-dimensional networks. Faseb J.
2002;16:1316-1318. PMID12060671
Wang E, Miller LD, Ohnmacht GA, Mocellin S, Perez-Diez A, Petersen D, Zhao Y, Simon R,
Powell JI, Asaki E, Alexander HR, Duray PH, Herlyn M, Restifo NP, Liu ET, Rosenberg SA,
Marincola FM. Prospective molecular profiling of melanoma metastases suggests classifiers of
immune responsiveness. Cancer Res. 2002;62:3581-3586. PMID12097256 (PMC2241738)
Andl CD, Mizushima T, Nakagawa H, Oyama K, Harada H, Chruma K, Herlyn M, Rustgi AK.
Epidermal growth factor receptor mediates increased cell proliferation, migration, and aggregation
19
Curriculum Vitae for Meenhard Herlyn, D.V.M., D.Sc.
229.
230.
231.
232.
233.
234.
235.
236.
237.
238.
239.
240.
241.
242.
243.
in esophageal keratinocytes in vitro and in vivo. J Biol Chem. 2003;278:1824-1830.
PMID12435727
Cook AL, Donatien PD, Smith AG, Murphy M, Jones MK, Herlyn M, Bennett DC, Leonard JH,
Sturm RA. Human melanoblasts in culture: expression of BRN2 and synergistic regulation by
fibroblast growth factor-2, stem cell factor, and endothelin-3. J Invest Dermatol. 2003;121:11501159. PMID14708619
Gruss CJ, Satyamoorthy K, Berking C, Lininger J, Nesbit M, Schaider H, Liu ZJ, Oka M, Hsu M-Y,
Shirakawa T, Li G, Bogenrieder T, Carmeliet P, El-Deiry WS, Eck SL, Rao JS, Baker AH, Bennet
JT, Crombleholme TM, Velazquez O, Karmacharya J, Margolis DJ, Wilson JM, Detmar M, Skobe
M, Robbins PD, Buck C, Herlyn M. Stroma formation and angiogenesis by overexpression of
growth factors, cytokines, and proteolytic enzymes in human skin grafted to SCID mice. J Invest
Dermatol. 2003;120:683-692. PMID12648235
Hingorani SR, Jacobetz MA, Robertson GP, Herlyn M, Tuveson DA. Suppression of
BRAF(V599E) in human melanoma abrogates transformation. Cancer Res. 2003;63:5198-5202.
PMID14500344
Hirst CJ, Herlyn M, Cattini PA, Kardami E. High levels of CUG-initiated FGF-2 expression cause
chromatin compaction, decreased cardiomyocyte mitosis, and cell death. Mol Cell Biochem.
2003;246:111-116. PMID12841351
Kalabis J, Patterson MJ, Enders GH, Marian B, Iozzo RV, Rogler G, Gimotty PA, Herlyn M.
Stimulation of human colonic epithelial cells by leukemia inhibitory factor is dependent on
collagen-embedded fibroblasts in organotypic culture. Faseb J. 2003;17:1115-1117.
PMID12692084
Li G, Kalabis J, Xu X, Meier F, Oka M, Bogenrieder T, Herlyn M. Reciprocal regulation of MelCAM
and AKT in human melanoma. Oncogene. 2003;22:6891-6899. PMID14534536
Liu ZJ, SnyderR, Soma A, Shirakawa T, Ziober BL, Fairman RM, Herlyn M, Velazquez OC.
VEGF-A and alphaVbeta3 integrin synergistically rescue angiogenesis via N-Ras and PI3-K
signaling in human microvascular endothelial cells. Faseb J. 2003;17:1931-1933. PMID14519669
Liu ZJ, Shirakawa T, Li Y, Soma A, Oka M, Dotto GP, Fairman RM, Velazquez OC, Herlyn M.
Regulation of Notch1 and Dll4 by vascular endothelial growth factor in arterial endothelial cells:
implications for modulating arteriogenesis and angiogenesis. Mol Cell Biol. 2003;23:14-25.
PMID12482957 (PMC140667)
Meier F, Caroli U, Satyamoorthy K, Schittek B, Bauer J, Berking C, Moller H, Maczey E, Rassner
G, Herlyn M, Garbe C. Fibroblast growth factor-2 but not Mel-CAM and/or beta3 integrin promotes
progression of melanocytes to melanoma. Exp Dermatol. 2003;12:296-306. PMID12823444
Satyamoorthy K, Li G, Gerrero MR, Brose MS, Volpe P, Weber BL, Van Belle P, Elder DE, Herlyn
M. Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both
BRAF mutations and autocrine growth factor stimulation. Cancer Res. 2003;63:756-759.
PMID12591721
Schaider H, Oka M, Bogenrieder T, Nesbit M, Satyamoorthy K, Berking C, Matsushima K, Herlyn
M. Differential response of primary and metastatic melanomas to neutrophils attracted by IL-8. Int
J Cancer. 2003;103:335-343. PMID12471616
Song JH, Song DK, Herlyn M, Petruk KC, Hao C. Cisplatin down-regulation of cellular Fasassociated death domain-like interleukin-1beta-converting enzyme-like inhibitory proteins to
restore tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human
melanoma cells. Clin Cancer Res. 2003;9:4255-4266. PMID14519653
Zhang H, Satyamoorthy K, Herlyn M, Rosdahl I. All-trans retinoic acid (atRA) differentially induces
apoptosis in matched primary and metastatic melanoma cells—a speculation on damage effect of
atRA via mitochondrial dysfunction and cell cycle redistribution. Carcinogenesis. 2003;24:185191. PMID12584166
Al Moustafa AE, Foulkes WD, Wong A, Jallal H, Batist G, Yu Q, Herlyn M, Sicinski P, AlaouiJamali MA. Cyclin D1 is essential for neoplastic transformation induced by both E6/E7 and
E6/E7/ErbB-2 cooperation in normal cells. Oncogene. 2004;23:5252-5256. PMID15229656
Berking C, Takemoto R, Satyamoorthy K, Shirakawa T, Eskandarpour M, Hansson J, VanBelle
PA, Elder DE, Herlyn M. Induction of melanoma phenotypes in human skin by growth factors and
ultraviolet B. Cancer Res. 2004;64:807-811. PMID14871803
20
Curriculum Vitae for Meenhard Herlyn, D.V.M., D.Sc.
244. Edwards RH, Ward MR, Wu H, Medina CA, Brose MS, Volpe P, Nussen-Lee S, Haupt HM, Martin
AM, Herlyn M, Lessin SR, Weber BL. Absence of BRAF mutations in UV-protected mucosal
melanomas. J Med Genet. 2004;41:270-272. PMID15060100 (PMC1735752)
245. Keswani SG, Katz AB, Lim FY, Zoltick P, Radu A, Alaee D, Herlyn M, Crombleholme TM.
Adenoviral mediated gene transfer of PDGF-B enhances wound healing in type I and type II
diabetic wounds. Wound Repair Regen. 2004;12:497-504. PMID15453831
246. Kim, SH, Kim K, Kwagh JG, Dicker DT, Herlyn M, Rustgi AK, Chen Y, El-Deiry WS. Death
induction by recombinant native TRAIL and its prevention by a caspase 9 inhibitor in primary
human esophageal epithelial cells. J Biol Chem. 2004;279:40044-40052. PMID15226295
247. Kim JW, Wong CW, Goldsmith JD, Song C, Fu W, Allion MB, Herlyn M, Al-Mehdi AB, Muschel
RJ. Rapid apoptosis in the pulmonary vasculature distinguishes non-metastatic from metastatic
melanoma cells. Cancer Lett. 2004;213:203-212. PMID15327836
248. Li G, Fukunaga M, Herlyn M. Reversal of melanocytic malignancy by keratinocytes is an Ecadherin-mediated process overriding beta-catenin signaling. Exp Cell Res. 2004;297:142-151;
Corrigendum 2005;305:436. PMID15194432
249. Margolis DJ, Cromblehome T, Herlyn M, Cross P, Weinberg L, Filip J, Propert K. Clinical protocol:
phase I trial to evaluate the safety of H5.020CMV.PDGF-b and limb compression bandage for the
treatment of venous leg ulcer: trial A. Hum Gene Ther. 2004;15:1003-1019. PMID15585116
250. van Kempen LC, Meier F, Egeblad M, Kersten-Niessen MJ, Garbe C, Weidle UH, Van Muijen GN,
Herlyn M, Bloemers HP, Swart GW. Truncation of activated leukocyte cell adhesion molecule: a
gateway to melanoma metastasis. J Invest Dermatol. 2004;122:1293-1301. PMID15140234
251. Yang L, Dan HC, Sun M, Liu Q, Sun XM, Feldman RI, Hamilton AD, Polokoff M, Nicosia SV,
Herlyn M, Sebti SM, Cheng JQ. Akt/protein kinase B signaling inhibitor-2, a selective small
molecule inhibitor of Akt signaling with antitumor activity in cancer cells overexpressing Akt.
Cancer Res. 2004;64:4394-4399. PMID15231645
252. Balint K, Xiao M, Pinnix CC, Soma A, Veres I, Juhasz I, Brown EJ, Capobianco AJ, Herlyn M, Liu
ZJ. Activation of Notch1 signaling is required for beta-catenin-mediated human primary melanoma
progression. J Clin Invest. 2005;115:3166-3176. PMID16239965 (PMC1257536)
253. Fang D, Nguyen TK, Leishear K, Finko R, Kulp AN, Hotz S, Van Belle PA, Xu X, Elder DE, Herlyn
M. A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res.
2005;65:9328-9337. PMID16230395
254. Gorgoulis VG, Vassiliou LV, Karakaidos P, Zacharatos P, Kotsinas A, Liloglou T, Venere M,
Ditullio RA Jr, Kastrinakis NG, Levy B, Kletsas D, Yoneta A, Herlyn M, Kittas C, Halazonetis TD.
Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions.
Nature. 2005;434:907-913. PMID15829965
255. Kumar SM, Acs G, Fang D, Herlyn M, Elder DE, Xu X. Functional erythropoietin autocrine loop in
melanoma. Am J Pathol. 2005;166:823-830. PMID15743794 (PMC1602342)
256. McArdle L, Rafferty MM, Satyamoorthy K, Maelandsmo GM, Dervan PA, Herlyn M, Easty DJ.
Microarray analysis of phosphatase gene expression in human melanoma. Br J Dermatol.
2005;152:925-930. PMID15888148
257. Price KL, Herlyn M, Dent CL, Gewert DR, Linge C. The prevalence of interferon-alpha
transcription defects in malignant melanoma. Melanoma Res. 2005;15:91-98. PMID15846141
258. Smalley KS, Brafford P, Haass NK, Brandner JM, Brown E, Herlyn M. Up-regulated expression of
zonula occludens protein-1 in human melanoma associates with N-cadherin and contributes to
invasion and adhesion. Am J Pathol. 2005;166:1541-1554. PMID15855653 (PMC1606406)
259. Zhang T, Somasundaram R, Berencsi K, Caputo L, Rani P, Guerry D, Furth E, Rollins BJ, Putt M,
Gimotty P, Swoboda R, Herlyn M, Herlyn D. CXC chemokine ligand 12 (stromal cell-derived factor
1 alpha) and CXCR4-dependent migration of CTLs toward melanoma cells in organotypic culture.
J Immunol. 2005;174:5856-5863. PMID15843590
260. Fang D, Leishear K, Nguyen TK, Finko R, Cai K, Fukunaga M, Li L, Brafford PA, Kulp AN, Xu X,
Smalley KS, Herlyn M. Defining the conditions for the generation of melanocytes from human
embryonic stem cells. Stem Cells. 2006;24:1668-1677. PMID16574754
261. Liu ZJ, Xiao M, Balint K, Soma A, Pinnix CC, Capobianco AJ, Velazquez OC, Herlyn M. Inhibition
of endothelial cell proliferation by Notch1 signaling is mediated by repressing MPAK and PI3K/Akt
pathways and requires MAML1. Faseb J. 2006;20:1009-1011. PMID16571776
21
Curriculum Vitae for Meenhard Herlyn, D.V.M., D.Sc.
262. Liu Z-J, Xiao M, Balint K, Smalley KSM, Brafford P, Qiu E, Pinnix CC, Li X, Herlyn M. Notch1
signaling promotes primary melanoma progression by activating Mitogen-Activated Protein
Kinase/Phosphatidylinositol 3-kKnase-Akt pathways and upregulating N-cadherin expression.
Cancer Res. 2006;66:4182-4190. PMID16618740
263. Oka M, Norose K, Matsushima K, Nishigori C, Herlyn M. Overexpression of IL-8 in the cornea
induces ulcer formation in the SCID mouse. Br J Ophthalmol. 2006;90:612-615. PMID16418304
(PMC1857070)
264. Oka M, Nishigori C, Kageshita T, Hsu M-Y, Penmatcha S, Herlyn M. Expression of PKC isoforms
in human melanocytic cells in situ. J Dermatol Sci. 2006;41:157-161. PMID16406501
265. Smalley KS, Haass NK, Brafford PA, Lioni M, Flaherty KT, Herlyn M. Multiple signaling pathways
must be targeted to overcome drug resistance in cell lines derived from melanoma metastases.
Molec Cancer Therapy. 2006;5:1136-1144. PMID16731745
266. Yu H, Fang D, Kumar SM, Li L, Nguyen TK, Acs G, Herlyn M, Xu X. Isolation of a novel
population of multipotent adult stem cells from human hair follicles. Am J Pathol. 2006;168:18791988. PMID16723703 PMC(1606635)
267. Hoek KS, Schlegel NC, Brafford P, Sucker A, Ugurel S, Kumar R, Weber BL, Nathanson KL,
Phillips DJ, Herlyn M, Schadendorf D, Dummer R. Metastatic potential of melanomas defined by
specific gene expression profiles with no BRAF signature. Pig Cell Res. 2006;19:290-302.
PMID16827748
268. Spoettl T, Hausmann M, Herlyn M, Gunckel M, Falk W, Herfarth H, Schoelmerich J, Rogler G.
Monocyte chemoattractant protein-1 (MCP-1) inhibits the intestinal-like differentiation of
monocytes. Clin Exp Immunol. 2006;145:190-199. PMID16792690 (PMC1942009)
269. Spoettl T, Hausmann M, Gunckel M, Herfarth H, Herlyn M, Schoelmerich J, Rogler G. A new
organotypic model to study cell interactions in the intestinal mucosa. Eur J Gastroenterol Hepatol.
2006;18:901-909. PMID16825910
270. Liu J, Kumar SKG, Yu D, Molton SA, McMahon M, Herlyn M, Thomas-Tikhonenko A, Fuchs SY.
Oncogenic BRAF regulates ß-Trep expression and NF-ĸB activity in human melanoma cells.
Oncogene. 2007;26:1954-1958. PMID170001349 (PMC1903341)
271. Dicker DT, Lerner J, Van Belle P, Barth SF, Guerry D 4th, Herlyn M, Elder DE, El-Deiry WS.
Differentiation of normal skin and melanoma using high resolution hyperspectral imaging. Cancer
Biol Ther. 2006;5:1033-1038. PMID16931902
272. Andl CD, Fargnoli BB, Okawa T, Bowser M, Takaoka M, Nakagawa H, Klein-Szanto A, Hua X,
Herlyn M, Rustgi AK. Coordinated functions of E-cadherin and TGFß receptor II in vitro and in
vivo. Cancer Res. 2006;66:9878-9885. PMID17047049 (PMC2996096)
273. Fukunaga-Kalabis M, Martinez G, Liu Z-J, Kalabis J, Mrass P, Weninger W, Firth SM, Planque N,
Perbal B, Herlyn M. CCN3 controls 3D spatial localization of melanocytes in the human skin
through DDR1. J Cell Biol. 2006;175:563-569. PMID17101694 (PMC2064593)
274. Oyama K, Okawa T, Nakagawa H, Takaoka M, Andl C, Kim S-H, Klein-Szanto A, Diehl JA, Herlyn
M, El-Deiry W, Rustgi AK. Akt induces senescence in primary esophageal epithelial cells but is
permissive for differentiation as revealed in organotypic culture. Oncogene. 2006;26:2353-2364.
PMID17043653 (PMC2996093)
275. King AJ, Patrick DR, Batorsky RS, Ho ML, Do HT, Zhang S-Y, Kumar R, Rusnak DW, Takle AK,
Wilson DM, Hugger E, Wang L, Karreth F, Lougheed JC, Lee J, Chau D, Stout TJ, May EW,
Rominger CM, Schaber MD, Luo L, Lakdawala AS, Adams JL, Contractor RG, Smalley KAM,
Herlyn M, Morrissey MM, Tuveson DA, Huang PS. Demonstration of a genetic therapeutic index
for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885. Cancer Res.
2006;66:11100-11105. PMID17145850
276. Smalley KSM, Contractor R, Haass NK, Kulp AN, Atilla-Gokcumen GE, Williams DS, Bregman H,
Flaherty KT, Soengas MS, Meggers E, Herlyn M. An organometallic protein kinase inhibitor
pharmacologically activates p53 and induces apoptosis in human melanoma cells. Cancer Res.
2007;67:209-217. PMID17210701
277. Lioni M, Brafford P, Andl A, Rustgi A, El-Deiry W, Herlyn M, Smalley KSM. Dysregulation of
Claudin-7 leads to loss of E-cadherin expression and the increased invasion of esophageal
squamous cell carcinoma cells. Am J Pathol. 2007;170:709-721. PMID17255337 (PMC1851859)
22
Curriculum Vitae for Meenhard Herlyn, D.V.M., D.Sc.
278. Smalley KS, Contractor R, Haass NK, Lee JT, Nathanson KL, Medina CA, Flaherty KT, Herlyn M.
Ki67 expression levels are a better marker of reduced melanoma growth following MEK inhibitor
treatment than phospho-ERK levels. Brit J Cancer. 2007;96:445-449. PMID17210701
(PMC2360037)
279. Meier F, Busch S, Lasithiotakis K, Kulms D, Garbe C, Maczey E, Herlyn M, Schitteck B.
Combining targeting MAPK and AKT signaling pathways is a promising strategy for melanoma
therapy. Br J Derm. 2007;156:1204-1213. PMID17388918
280. Kumar SM, Yu H, Edwards R, Chen L, Kazianis S, Brafford P, Acs G, Herlyn M, Xu X. Mutant
V600E BRAF increases hypoxia inducible factor-1alpha expression in melanoma. Cancer Res.
2007;67:3177-3184. PMID17409425
281. Thomas RK, Baker AC, Debiasi RM, Winckler W, Laframboise T, Lin WM, Wang M, Feng W,
Zander T, Macconnaill LE, Lee JC, Nicoletti R, Hatton C, Goyette M, Girard L, Majmudar K,
Ziaugra L, Wong KK, Gabriel S, Beroukhim R, Peyton M, Barretina J, Dutt A, Emery C, Greulich
H, Shah K, Sasaki H, Gazdar A, Minna J, Armstrong SA, Mellinghoff IK, Hodi FS, Dranoff G,
Mischel PS, Cloughesy TF, Nelson SF, Liau LM, Mertz K, Rubin MA, Moch H, Loda M, Catalona
W, Fletcher J, Signoretti S, Kaye F, Anderson KC, Demetri GD, Dummer R, Wagner S, Herlyn M,
Sellers WR, Meyerson M, Garraway LA. High-throughput oncogene mutation profiling in human
cancer. Nature Genet. 2007;39:347-351. PMID17293865; Corrigendum 2007;39:567.
PMID17392811
282. Seidl H, Richtig E, Tilz H, Stefan M, Schmidbauer U, Asslaber M, Zatloukal K, Herlyn M, Schaider
H. Profiles of chemokine receptors in melanocytic lesions: de novo expression of CXCR6 in
melanoma. Hum Pathol. 2007;38:768-780. PMID17306330
283. Lopez-Bergami P, Huang C, Goydos JS, Yip D, Bar-Eli M, Herlyn M, Smalley KS, Mahale A,
Eroshkin A, Aaronson S, Ronai Z. Re-wired ERK-JNK signaling pathways in melanoma. Cancer
Cell. 2007;11:447-460. PMID17482134 (PMC1978100)
284. Spittle C, Ward MR, Nathanson KL, Gimotty PA, Rappaport E, Brose MS, Medina A, Letrero R,
Herlyn M, Edwards RH. Application of a BRAF pyrosequencing assay for mutation detection and
copy number analysis in malignant melanoma. J Molec Diagn. 2007;9:464-471. PMID17690212
(PMC1975103)
285. Kumar KGS, Liu J, Yu D, Thomas-Tikhonenko A, Herlyn M, Fuchs SY. Raf inhibitor stabilizes
receptor for type I interferon but inhibits its anti-proliferative effects in human malignant melanoma
cells. Cancer Biol Ther. 2007;6:1437-1441. PMID17873516 (PMC2254442)
286. Wenke AK, Kjellman C, Lundgren-Akerlund E, Uhlmann C, Haass NK, Herlyn M, Bosserhoff AK.
Expression of integrin alpha 10 is induced in melanoma. Cell Oncol. 2007;29:373-386.
PMID17726260
287. Lin WM, Baker AC, Beroukhim R, Winkler W, Feng W, Marmion J, Laine E, Greulich H, Tseng H,
Gates C, Hodi FS, Dranoff GM, Sellers WR, Thomas RK, Meyerson M, Golub TR, Dummer R,
Herlyn M, Getz G, Garraway LA. Modeling genomic diversity and tumor dependency in malignant
melanoma. Cancer Res. 2008;68:664-673. PMID18245465
288. Okawa T, Michaylira CZ, Kalabis J, Stairs DB, Nakagawa H, Andl C, Johnstone CN, Klein-Szanto
AI, El-Deiry WS, Cukierman E, Herlyn M, Rustgi AK. The functional interplay between EGFR,
hTERT activation and p53 mutation in esophageal epithelial cells with activation of stromal
fibroblasts induce tumor development, invasion and differentiation. Genes Devel. 2007;21:27882803. PMID17974918 (PMC2045132)
289. Fukunaga-Kalabis M, Martinez G, Telson SM, Liu Z-J, Balint K, Juhasz I, Elder DE, Perbal B,
Herlyn M. Loss of CCN3 expression as a potential mechanism for melanoma progression.
Oncogene. 2007;27:2552-2558. PMID17968313 (PMC N/A)
290. Han M-J, Herlyn M, Fisher AB, Speicher DW. Microscale solution IEF combined with 2-D DIGE
substantially enhances analysis depth of complex proteomes such as mammalian cell and tissue
extracts. Electrophoresis. 2008;29:695-705. PMID18186533 (PMC N/A)
291. Haass NK, Sproesser K, Nguyen TK, Contractor R, Medina CA, Nathanson KL, Herlyn M,
Smalley KSM. The MEK inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma
cells and tumor regression when combined with docetaxel. Clin Cancer Res. 2008;14:230-239.
PMID18172275 (PMC N/A)
23
Curriculum Vitae for Meenhard Herlyn, D.V.M., D.Sc.
292. Tsai J, Lee JT, Wang W, Zhang J, Cho H, Mamo S, Bremer R, Gilette S, Kong J, Haass NK,
Sproesser K, Li L, Smalley KSM, Fong D, Zhu Y-L, Marimuthu A, Nguyen H, Lam B, Liu J,
Cheung I, Rice J, Suzuki Y, Liu C, Settachatgul C, Shellooe R, Cantwell J, Kim S-H, Schlessinger
J, Zhang KYJ, West B, Powell B, Habets G, Zhang C, Ibrahim PN, Hirth P, Artis DR, Herlyn M,
Bollag G. Discovery of a novel selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Nat Acad Sc U S A. 2008;26:3041-3049. PMID18287029 (PMC2268581)
293. Zecchini S, Bianchi M, Colombo N, Fasani R, Goisis G, Casadio C, Viale G, Liu J, Herlyn M,
Godwin A, Nuciforo P, Cavallaro U. The differential role of L1 in normal and transformed ovarian
surface epithelium. Cancer Res.2008;68:1110-1118. PMID18281486 (PMC N/A)
294. Gordon A, Kozin ED, Keswani SG, Vaikunth SS, Katz AB, Zoltick PW, Favata M, Radu AP,
Soslowsky LJ, Herlyn M, Crombleholme TM. Permissive environment in postnatal wounds by
adenoviral-mediated overexpression of the anti-inflammatroy cytokine interleukin-10 prevents scar
formation. Wound Repair Regen. 2008;16:70-79. PMID18086289 (PMC N/A)
295. Sigalotti L, Covre A, Zabierowski S, Himes B, Colizzi F, Natali PG, Herlyn M, Maio M. Cancer
testis antigens in human melanoma stem cells: expression, distribution and methylation status. J
Cell Physiol. 2008;215:287-291. PMID1802582 (PMC N/A)
296. Noma K, Smalley KSM, Lioni M, Naomoto Y, Tanaka N, El-Deiry W, King AJ, Nakagawa H,
Herlyn M. An essential role for stromal fibroblasts and transformating growth factors (TGF)-ß in
esophageal squamous cell carcinoma-induced angiogenesis. Gastroenterol. 2008;134:19811993. PMID18439605 (PMC2562524)
297. Maksimoska J, Williams DS, Atilla-Gokcumen GE, Smalley KSM, Carroll PJ, Webster RD,
Filippakopoulos P, Knapp S, Herlyn M, Meggers E. Isostructural ruthenium and osmium
complexes display highly similar bioactivities. Chemistry. 2008;14:4816-4822. PMID18425743
(PMC2753370)
298. Alfano RW, Leppla SH, Liu S, Bugge TH, Herlyn M, Smalley KS, Duesberg NS, Houghton A,
Frankel AE. Cytotoxicity of the engineered matrix metalloproteinase-activated anthrax lethal toxin
is dependent on gelatinase expression and B-RAF status in human melanoma cells. Molec
Cancer Therap. 2008;8:1218-1226. PMID18483309 (PMC2757055)
299. Kalabis J, Li G, Fukunaga-Kalabis M, Rustgi A, Herlyn M. Endothelin-3 stimulates survival of
goblet cells in organotypic cultures of human colonic epithelium. Am J Physiol - GI Liver Physiol.
2008;295:G1182-1189. PMID18832450 (PMC2604801)
300. Smalley KSM, Contractor R, Nguyen TK, Xiao M, Medinca A, Edwards R, Muthusamy V, King AJ,
Flaherty KT, Bosenberg M, Herlyn M, Nathanson KL. Identification of a novel sub-group of
melanomas with kit/cyclin-dependent kinase-4 overexpression. Cancer Res. 2008;68:5743-5752.
PMID18632627 (PMC2615688)
301. Xie P, Williams DS, Atilla Gokumen GE, Milk L, Xiao M, Smalley KS, Herlyn M, Meggers E,
Marmorstein R. Structure-based design of an organoruthenium phosphotidyl-inositol-3-kinase
inhibitor revieals a switch governing lipid kinase potency and selectivity. ACS Chem Biol.
2008;3:305-316. PMID18484710 (PMC3618672)
302. Smalley KSM, Lioni M, Palma MD, Xiao M, Desai B, Eghazi S, Hansson J, Hong W, King AJ,
Flaherty KT, Herlyn M, Nathanson KL. Cyclin D1 mediates BRAF inhibitor resistance in a sub-set
of BRAF-V600E mutated melanomas. Molec Can Ther. 2008;7:2876-2883. PMID18790768
(PMC2651569)
303. Lioni M, Noma K, Snyder A, Rustgi A, Diehl JA, Herlyn M, Smalley K. Bortezomib-induced cellular
stress via the p38 MAPK pathway leads to a DNA damage response and apoptosis in esophageal
squamous cell carcinoma cells. Molec Cancer Ther. 2008;7:2866-2875. PMID18790767
(PMC2903039)
304. Harada H, Nakagawa H, Takaoka M, Lee J, Herlyn J, Diehl JA, Rustgi AK. Cleavage of MCM2
licensing proteins fosters senescence in human keratinocytes. Cell Cycle. 2008;7:3534-3538.
PMID19001876 (PMC2736109)
305. Kalabis J, Oyama K, Okawa T, Nakagawa H, Michaylira CZ, Stairs DB, Figueiredo JL, Mahmood
U, Diehl JA, Herlyn M, Rustgi AK. A sub-population of mouse esophageal basal cells has
properties of stem cells with the capacity for self-renewal and lineage specification. J Clin Invest.
2008;118:3860-3869. PMID19005570 (PMC2579884)
24
Curriculum Vitae for Meenhard Herlyn, D.V.M., D.Sc.
306. Smalley KSM, Xiao M, Villanueva J, Nguyen TK, Flaherty KT, Letrero R, Nathanson KL, Herlyn M.
CRAF inhibition induces Bcl-2 dependent apoptosis in melanomas with non V600E BRAF
mutations. Oncogene. 2009;28:85-94. PMID18794803 (PMC2898184)
307. Greshok J, Nathanson K, Medina A, Ward MR, Herlyn M, Weber BL, Zaks TZ. Distinct patterns of
DNA copy number alterations associate with BRAF mutations in melanomas and melanoma
derived cell lines. Genes, Chromosomes, Cancer. 2009;48:419-428. PMID19226609
(PMC2885833)
308. Yu H, McDaid R, Lee J, Possik P, Kumar SM, Elder DE, Van Belle P, Gimotty P, Guerra M,
Hammond R, Nathanson KL, Dalla Plama M, Herlyn M, Xu X. Role of BRAF mutation and p53
inactivation during transformation of a sub-population of primary human melanocytes. Am J
Pathol. 2009;174:2367-2377. PMID19389934 (PMC2684200)
309. Pinnix CC, Lee JT, Liu Z-J, McDaid R, Balint K, Beverly LJ, Brafford PA, Xiao M, Himes B,
Zabierowski SE, Yashiro-Ohtani Y, Nathanson KL, Bengston A, Pollock PM, Weeraratna AT,
Nickoloff BJ, Pear WE, Capobianco AJ, Herlyn M. Active Notch1 protein confers a transformed
phenotype to primary human melanocytes. Cancer Res. 2009;69:5312-5320. PMID19549918
(PMC2755513)
310. Degenhardt Y, Huang J, Horiates G, Nathanson K, Yang X, Herlyn M, Weber B. Distinct MHC
gene expression patterns during progression of melanoma. Genes, Chromosomes, Cancer.
2010;49:144-154. PMID19907984 (PMC2796267)
311. Katz AB, Keswani SG, Habli M, Lim FY, Zoltick PW, Midrio P, Kozin ED, Herlyn M, Crombleholme
TM. Placental gene transfer: transgene screening in mice for trophic effects on the placenta. Am J
Obstet Gynocol. 2009;201:499.e1-8. PMID19716119. (PMC2885953)
312. Li L, Fukunaga-Kalabis M, Yu H, Xu X, Kong J, Lee JT, Herlyn M. Human dermal stem cells
differentiate into functional epidermal melanocytes. J Cell Sci. 2010;123:853-860. PMID20159965
(PMC2831759)
313. Ohashi S, Natsuizaka M, Wong GS, Michaylira CZ, Grugan KD, Nakagawa N, Klein-Szanto AJ,
Herlyn M, Diehl JA, Rustgi AK, Nakagawa H. EGFR and mutant p53 expand esophageal cellular
subpopulation capable of epithelial-to-mesenchymal transition through ZEB transcription factors.
Cancer Res. 2010;70:4174-4184. PMID20424117 (PMC3007622)
314. Basu D, Nguyen T-T, Montone KT, Zhang G, Wang L-P, Diehl JA, Rustgi AK, Lee JT, Weinstein
GS, Herlyn M. Mesenchymal sub-populations within squamous cell carcinomas exhibiting
chemoresistance and phenotypic plasticity. Oncogene. 2010;29:4170-4182. PMID20498638
(PMC3039880)
315. Roesch A, Fukunaga-Kalabis M, Schmidt EC, Zabierowski SE, Brafford PA, Vultur A, Basu D,
Gimotty P, Vogt T, Herlyn M. A temporarily distinct subpopulation of slow-cycling melanoma cells
is required for continuous tumor growth. Cell. 2010;141:583-594. PMID204782552
(PMC2882693).
316. Natsuizaka M, Ohashi S, Wong G, Ahmadi A, Kalman R, Budo D, Klein-Szanto A, Herlyn M, Diehl
A, Nakagawa H. Insulin-like growth factor binding protein-3 promotes transforming growth factorß1-mediated epithelial-to-mesenchymal transition and motility in transformed human esophageal
cells. Carcinogenesis. 2010;31:1344-1353. PMID20513670 (PMC2915630)
317. Michaylira CZ, Wong GS, Miller CG, Gutierrez CM, Nakagawa H, Hammond R, Klein-Szanto AJ,
Lee JS, Kim SB, Herlyn M, Diehl JA, Gimotty P, Rustgi AK. Periostin, a cell adhesion molecule,
facilitates invasion in the tumor microenvironment and annotates a novel tumor-invasive signature
in esophageal cancer. Cancer Res. 2010;70:5281-5291. PMID20516120 (PMC3274349)
318. Grugan KD, Miller CG, Yao Y, Michaylira CZ, Ohashi S, Klein-Szanto AJ, Diehl JA, Herlyn M, Han
M, Nakagawa H, Rustgi AK. Fibroblast-secreted hepatocyte growth factor plays a functional role
in esophageal cell carcinoma invasion. Proc Natl Acad Sci U S A. 2010;107:11026-11031.
PMID20534479 (PMC2890722)
319. Ohashi S, Natsuizaka M, Yashiro-Ohtani Y, Kalman RA, Nakagawa M, Wu L, Klein-Szanto AJ,
Herlyn M, Diehl JA, Kathz JP, Pear WS, Seykora JT, Nakagawa H. NOTCH1 and NOTCH3
coordinate esophageal squamous differentiation through a CSL-dependent transcriptional
network. Gastroenterol. 2010;139:2113-2123. PMID20801121 (PMC2997138)
25
Curriculum Vitae for Meenhard Herlyn, D.V.M., D.Sc.
320. Fukunaga-Kalabis M, Martinez G, Nguyen T-TK, Kim D, Santiago-Walker A, Roesch A, Herlyn M.
Tenascin promotes melanoma progression by maintaining the ABCB5-positive side population.
Oncogene. 2010;29:6115-6124. PMID2072997 (PMC2991494)
321. Aggarwal P, Vaites LP, Kim JK, Mellert H, Nakagawa H, Herlyn M, Rustgi A, McMahon SB, Diehl
JA. Nuclear Cyclin D1/CDK4 minase regulates CUL4 expression and triggers neoplastic growth
via activation of the PRMT5 methyltransferase. Cancer Cell. 2010;18:329-340. PMID20951943
(PMC2957477)
322. Lee J, Li L, Brafford P, Sproesser K, Haass N, Smalley K, van den Eijnden M, Halloran M, Tsai J,
Bollag G, Herlyn M. PLX4032, a potent inhibitor of the B-Raf V600E oncogene, selectively
inhibitrs V600E-positive melanomas. Pig Cell Mel Res. 2010;23:820-827. PMID20973932
(NIHMS452487, PMC in Progress)
323. Han M-J, Wang H, Beer LA, Tang H-Y, Herlyn M, Speicher D. A systems biology analysis of
metastatic melanoma using in-depth three-dimensional protein profiling. Proteomics.
2010;10:4450-4462. PMID21082759 (PMC3070844)
324. Villanueva J, Vultur A, Lee JT, Somasundaram R, Fukunaga-Kalabis M, Cipolla AK, Wubenhorst
B, Xu X, Gimotty PA, Kee D, Santiago-Walker AE, Letrero R, D’Andrea K, Pushparajan A,
Hayden JE, Dahlman K, Laquerre S., McArthur G, Sosman J, Nathanson KL, Herlyn M. Acquired
resistance to BRAF inhibitors mediated by an A/B/C RAF kinase switch in melanoma can be
overcome by co-targeting MEK and IGF-1R/PI3K. Cancer Cell. 2010;18:683-695. PMID21156289
(PMC3026446)
325. Thurber AE, Douglas G, Sturm EC, Zabierowski SE, Smit DJ, Ramakrishnan SN, Hacker E,
Leonard JH, Herlyn M, Sturm RA. Inverse expression of BRN2 and MITF transcription factors in
melanoma spheres and tumor xenografts regulate the NOTCH pathway. Oncogene.
2011;30:3036-3048. PMID21358674 (PMC3591523)
326. Zabierowski SE, Baubet V, Himes B, Li L, Fukunaga-Kalabis M, Patel S, McDaid R, Guerra M,
Gimotty P, Dahmane N, Herlyn M. Direct reprogramming of melanocytes to neural crest stem-like
cells by one defined factor. Stem Cells. 2011;1752-62. PMID21948558 (PMC3615703)
327. Magnitsky S, Roesch A, Herlyn M, Glickson JD. In vivo and ex vivo MR imaging of slowly cycling
melanoma cells. Magn Reson Med. 2011;66:1362-1372. PMID21523820 (PMC3145816)
328. Basu D, Montone KT, Wang L-P, Gimotty PA, Hammond R, Diehl JA, Rustgi AK, Lee JT,
Rasanen K, Weinstein GS, Herlyn M. Detecting and targeting mesenchymal-like subpopulations
within squamous cell carcinomas. Cell Cycle. 2011;10:2008-2016. PMID21558812
(PMC3154419)
329. Li L, Fukunaga-Kalabis M, Herlyn M. The three-dimensional human skin reconstruct model: a tool
to study normal skin and melanoma progression. J Vis Exp. 2011;54:e2937. PMID21847077
(PMC3159964)
330. Ohashi S, Natsuizaka M, Naganuma S, Kagawa S, Kimura S, Itoh H, Kalman RA, Nakagawa M,
Darling DS, Basu D, Gimotty PA, Klein-Szanto AJ, Diehl JA, Herlyn M, Nakagawa H. A NOTCH3mediated squamous cell differentiation program limits expansion of EMT competent cells that
express the ZEB transcription factors. Cancer Res. 2011;71:6636-6847. PMID21890822
(PMC3206139)
331. Blanck S, Cruchter T, Vultur A, Riedel R, Harms K, Herlyn M, Meggers E. Organometallic
pyridylnaphthalimide complexes as protein kinase inhibitors. Organometallics. 2011;30:45984606. PMID21918590 (PMC3170819)
332. Flach EH, Rebecca VW, Herlyn M, Smalley KSM, Anderson ARA. Fibroblasts contribute to
melanoma tumor growth and drug resistance. Molecular Pharm. 2011;8:2039-2049.
PMID22067046 (PMC3235959)
333. Feng Y, Barile E, De SK, Stebbins JL, Cortez A, Aza-Blanc P, Villanueva J, Herlyn M, Krajewski
S, Melecchia M, Ronai ZA, Chiang GG. Effective inhibition of melanoma by BI-69A11 is mediated
by dual targeting of the AKT and NF-kB pathways. Pigm Cell Mel Res. 2011;24:703-713.
PMID21592316 (PMC3076536)
334. Kalabis J, Wong GS, Vega ME, Natsuizaka M, Robertson ES, Herlyn M, Nakagawa H, Rustgi AK.
Isolation and characterization of mouse and human esophageal epithelial cells in 3D organotypic
culture. Nature Protocols. 2012;7:235-246. PMID22240585 (PMC3505594)
26
Curriculum Vitae for Meenhard Herlyn, D.V.M., D.Sc.
335. Pinc A, Somasundaram R, Wagner C, Hörmann M, Karanikas G, Jalili A, Bauer W, Brunner P,
Grabmeier-Pfisterhammer K, Gschaider M, Lai CY, Hsu M-Y, Herlyn M, Stingl G, Wagner SN.
Targeting CD20 in melanoma patients at high risk of disease recurrence. Mol Ther. 2012;20:10561062. PMID22354376 (PMC3345981)
336. Wenzel V, Roedl D, Gabriel D, Gordon LB, Herlyn M, Schneider R, Ring J, Djabali K. Naïve adult
stem cells from patients with Hutchinson-Gilford progeria syndrome express low levels of progerin
in vivo. Biol Open. 2012;1:516-526. PMID23213444 (PMC3509444)
337. Wang T, Ge Y, Xiao M, Lopez-Coral A, Azuma R, Somasundaram R, Zhang G, Wei Z, Xu X,
Rauscher FJ, Herlyn M, Kaufman RE. Melanoma-derived conditioned media efficiently induce the
differentiation of monocytes to macrophages that display a highly invasive gene signature. Pigm
Cell Mel Res. 2012;25:493-505. PMID22498258 (PMC3615702)
338. Qin J, Xie P, Ventocilla C, Zhou G, Vultur A, Chen Q, Liu Q, Herlyn M, Winkler JD, Marmorstein
R. Identification of a novel family of BRAFV600E inhibitors. J Med Chem. 2012;55:5220-5230.
PMID22537109 (PMC3383862)
339. Furney SJ, Turajlic S, Fenwick K, Lambros MB, Mackay A, Ricken G, Mitsopoulos C, Kozarewa I,
Hakas J, Zvelebil M, Lord CJ, Ashworth A, Reis-Filho JS, Herlyn M, Murata H, Marais R. Genomic
characterisation of acral melanoma cell lines. Pigment Cell Mel Res. 2012;25:488-492.
PMID22578220 (PMC – N/A)
340. John JK, Paraiso KHT, Rebecca VW, Cantini LP, Abel EV, Pagano N, Meggers E, Mathew R,
Krepler C, Izumi V, Fang B, Koomen JM, Messina JL, Herlyn M, Smalley KSM. GSK3ß inhibition
blocks melanoma cell/host interactions by downregulating N-cadherin expression and decreasing
FAK phosphorylation. J Invest Dermatol. 2012;132:2818-2827. PMID22810307 (PMC3479306)
341. Naganuma S, Whelan KA, Natsuizaka S, Kinugasa H, Chang S, Subramanian H, Rhoades B,
Ohashi S, Itoh H, Herlyn M, Diehl JA, Gimotty PA, Klein-Szanto AJ, Nakagawa H. Notch receptor
inhibition reveals the importance of cyclin D1 and Wnt signaling in invasive esophageal squamous
cell carcinoma. Am J Cancer Res. 2012;2:459-475. PMID22860235 (PMC3410579)
342. Tchou J, Kossenkov AV, Chang L, Satija C, Herlyn M, Showe LC, Puré E. Human breast cancer
associated fibroblasts exhibit subtype specific gene expression profiles. BMC Med Genomics.
2012;5:39. PMID22954256 (PMC3505468)
343. Chae YC, Caino MC, Lisanti S, Gosh JC, Dohi T, Danial NN, Villanueva J, Ferrero S, Vaira V,
Santambrogio L, Bosari S, Languino LR, Herlyn M, Altieri DC. Control of tumor bioenergetics and
survival stress signaling by mitochondrial HSP90. Cancer Cell. 2012;22:331-344. PMID22975376
(PMC3615709)
344. Kong X, Qin J, Li Z, Vultur A, Tong L, Feng E, Rajan G, Liu S, Lu J, Liang Z, Zheng M, Zhu W,
Jiang H, Herlyn M, Liu H, Marmorstein R, Luo C. Development of a novel class of B-RAF
(V600E)-selective inhibitors through virtual screening and hierarchical hit optimization. Org Biomol
Chem. 2012;10:7402-7417. PMID22875039 (PMC3427755)
345. Schayowitz A, Bertenshaw G, Jeffries E, Schatz T, Cotton J, Villanueva J, Herlyn M, Krepler C,
Vultur A, Xu W, Yu GH, Schuchter L, Clark DP. Functional profiling of live melanoma samples
using a novel automated platform. PLos One. 2012;7:e52760. PMID23285177 (PMC3532357)
346. Balaburski GM, Leu JI, Beeharry N, Hayik S, Andrake MD, Zhang G, Herlyn M, Villanueva J,
Dunbrack RL, Yen T, George DL, Murphy ME. A modified HSP70 inhibitor shows broad activity as
an anticancer agent. Mol Cancer Res. 2013;11:219-229. PMID23303345 (PMC3606282)
347. Krepler C, Chunduru SK, Halloran MB, He X, Xiao M, Vultur A, Villanueva J, Mitsuuchi Y, Neiman
EM, Benetatos C, Nathanson KL, Amaravadi RK, Pehamberger H, McKinlay M, Herlyn M. The
novel SMAC inhibitor birinapant exhibits potent activity against human melanoma cells. Clin
Cancer Res. 2013;19:1784-1794. PMID23403634 (PMC3618595)
348. Kastl A, Dieckman S, Wähler K, Völker T, Kastl L, Shannan B, Harms K, Ocker M, Parak W,
Herlyn M, Meggers E. Rhenium complexes with visible-light-induced anticancer activity.
Organometallic Med Chem. 2013;8:924-927. PMID23568508 (PMC3665699)
349. Desai BM, Villanueva J, Nguyen T-TK, Lioni M, Xiao M, Kong J, Krepler C, Vultur A, Flaherty KT,
Nathanson KL, Smalley KSM, Herlyn M. The anti-melanoma activity of dinaciclib, a cyclindependent kinase inhibitor, is dependent on p53 signaling. PLoS One. 2013;8(3):e59588.
PMID23527225 (PMC3601112)
350. Aird KM, Zhang G, Li H, Tu Z, Bitler BG, Garipov A, Wu H, Wei Z, Wagner SN, Herlyn M, Zhang
27
Curriculum Vitae for Meenhard Herlyn, D.V.M., D.Sc.
351.
352.
353.
354.
355.
356.
357.
358.
359.
360.
361.
362.
363.
R. Suppression of nucleotide metabolism underlies the establishment and maintenance of
oncogene-induced senescence. Cell Rep. 2013;3:1-4. PMID23562156 (PMC3840499 [Available
on 2014/4/25]; NIHMS466586)
Roesch A, Vultur A, Bogeski I, Wang H, Zimmermann KM, Speicher D, Körbel C, Laschke MW,
Gimotty PA, Philipp SE, Krause E, Pätold S, Villanueva J, Krepler C, Fukunaga-Kalabis M, Hoth
M, Bastian B, Vogt T, Herlyn M. Overcoming intrinsic multi-drug resistance in melanoma by
blocking the mitochondrial respiratory chain of slow-cycling JARID1B(high) cells. Cancer Cell.
2013;23:811-825. PMID23764003 (PMC3810180 [Available on 2014/6/10])
Reuveni H, Flashner-Abramson E, Steiner L, Makedonski K, Song R, Shir A, Herlyn M, Bar-Eli M,
Levitzki A. Therapeutic destruction of insulin receptor substrates for cancer treatment. Cancer
Res. 2013;73:4383-4394. PMID23651636
Kwak J, Gallagher M, Ozdener MH, Wysocki CJ, Goldsmith BR, Isamah A, Faranda A,
Fakharzadeh SS, Herlyn M, Johnson ATC, Preti G. Volatile biomarkers from human melanoma
cells. J Chromatography B Analyt Technol Biomed Life Sci. 2013;931:90-96. PMID23770738
Villanueva J, Infante J, Krepler C, Reyes-Uribe P, Samanta M, Chen H-Y, Li B, Swoboda R,
Wilson M, Vultur A, Fukunaga-Kalabis M, Wubbenhorst B, Chen TY, Liu Q, Sproesser K,
DeMarini D, Gilmer T, Martin A-M, Marmorstein R, Schultz D, Speicher D, Karakousis G, Xu W,
Amaravadi R, Xu X, Schuchter L, Herlyn M, Nathanson K. Concurrent MEK2 mutation and BRAF
amplification confer resistance to BRAF and MEK inhibitors in melanoma. Cell Reports.
2013;4:1090-1099. PMID24055054
Basu D, Bewley AF, Sperry SM, Montone KT, Gimotty PA, Rasanen K, Facompre ND, Weinstein
GS, Nakagawa H, Diehl JA, Rustgi AK, Herlyn M. EGFR inhibition promotes an aggressive
invasion pattern mediated by mesenchymal-like tumor cells within squamous cell carcinomas.
Molec Cancer Ther. 2013;12:2176-2186. PMID23939378 (PMC3796003 [Available on 2014/10/1])
Lee EK, Lian Z, D'Andrea K, Letrero R, Sheng W, Liu S, Diehl N, Barbash O, Schuchter LM,
Amaravadi RK, Xu X, Herlyn M, Nathanson KL, Diehl JA. The FBXO4 tumor suppressor functions
as a barrier to BRAFV600E-dependent metastatic melanoma. Mol Cell Biol. 2013;33:4422-4433.
PMID24019069
Rasänen K, Speicher K, Valiga A, Tang H-Y, Zhang G, Perego M, Somasundaram R, Li L,
Sriwasdi S, Klein-Szanto A, Basu D, Rustgi AK, Speicher DW, Herlyn M. Comparative secretome
analysis of epithelial and mesenchymal subpopulations of head and neck squamous cell
carcinoma identifies S100A4 as a potential therapeutic target. Molec Cell Proteomics.
2013;12(12):3778-92. PMID24037664
Wang T, Ge Y, Xiao M, Lopez-Coral A, Li L, Roesch A, Huang C, Alexander P, Vogt T, Xu X,
Hwang W-T, Lieu M, Belser E, Liu R, Somasundaram R, Herlyn M, Kaufman RE. SECTM1
produced by tumor cells attracts human monocytes via CD7-mediated activation of the PI3K
pathway. J Invest Dermatol. 2014; 134:1108-1118. PMID24157461
Wong GS, Lee JS, Park YY, Klein-Szanto AJ, Waldron TJ, Cukierman E, Herlyn M, Gimotty P,
Nakagawa H, Rustgi AK. Periostin cooperates with mutant p53 to mediate invasion through the
induction of STAT1 signaling in the esophagus tumor microenvironment. Oncogenesis.
2013;2:e59. PMID23917221 (PMC3759121)
O'Connell M, Marchbank K, Webster M, Valiga A, Kaur A, Vultur A, Li L, Herlyn M, Villanueva J,
Liu Q, Yin X, Widura S, Nelson J, Ruiz N, Camilli T, Indig FE, Flaherty K, Wargo J, Frederick DT,
Cooper Z, Nair S, Amaravadi R, Schuchter L, Karakousis G, Xu W, Xu X, Weeraratna AT.
Hypoxia induces phenotypic plasticity and therapy resistance in melanoma via the tyrosine kinase
receptors ROR1 and ROR2. Cancer Discovery. 2013;3(12):1378-93. PMID24104062
Nallet-Staub F, Marsaud V, Li L, Gilbert C, Dodier S, Bataille V, Sudol M, Herlyn M, Mauviel A.
Pro-invasive activity of the hippo pathway effectors YAP and TAZ in cutaneous melanoma. J
Invest Dermatol. 2014;134:123-132. PMID23897276
Vultur A, Villanueva J, Krepler C, Rajan G, Chen Q, Li L, Gimotty P, Wilson M, Hayden J, Keeney
F, Nathanson KL, Herlyn M. MEK inhibition affects STAT3 signaling and invasion in human
melanoma cell lines. Oncogene 2014; 33: 1850-1861. PMID23624919 (PMC3769503)
Ma X-H, Pioa S-F, Dey S, Mcafee Q, Karakousis G, Villanueva J, Hart LS, Levi S, Hu J, Zhang G,
Lazova R, Klump V, Pawelek JM, Xu X, Schuchter LM, Davies MA, Herlyn M, Winkler J,
Koumenis C, Amaravadi RK. Targeting ER stress induced autophagy overcomes resistance to
28
Curriculum Vitae for Meenhard Herlyn, D.V.M., D.Sc.
BRAF inhibition in melanoma. J Clin Invest. 2014;124:1406-1417. PMID24569374
364. Hayashizaki Y et al. FANTOM consortium and the RIKEN PMI and CLST (DGT) (...Herlyn M...).
Nature. 2014;507:462-470. PMID 24670764
365. Andersson R, Gebhard C, Miguel-Escalada I, Hoof I, Bornholdt J, Boyd M, Chen Y, Zhao X,
Schmidl C, Suzuki T, Ntini E, Arner E, Valen E, Li K, Schwarzfischer L, Glatz D, Raithel J, Lilje B,
Rapin N, Bagger FO, Jørgensen M, Andersen PR, Bertin N, Rackham O, Burroughs AM, Baillie
JK, Ishizu Y, Shimizu Y, Furuhata E, Maeda S, Negishi Y, Mungall CJ, Meehan TF, Lassmann T,
Itoh M, Kawaji H, Kondo N, Kawai J, Lennartsson A, Daub CO, Heutink P, Hume DA, Jensen TH,
Suzuki H, Hayashizaki Y, Müller F; FANTOM Consortium (...Herlyn M...), Forrest AR, Carninci P,
Rehli M, Sandelin A. An atlas of active enhancers across human cell types and tissues. Nature.
2014 Mar 27;507(7493):455-61. PMID24670763
366. Morikawa H, Ohkura N, Vandenbon A, Itoh M, Nagao-Sato S, Kawaji H, Lassmann T, Carninci P,
Hayashizaki Y, Forrest AR, Standley, DM, Date H, Sakaguchi S; FANTOM Consortium (...Herlyn
M...). Differential roles of epigenetic changes and Foxp3 expression in regulatory T cell-specific
transcriptional regulation. Proc Natl Acad Sci USA. 2014;111:5289-5294. PMID24706905
367.
Peng H, Talebzadeh-Farrooji M, Osborne MJ, Prokop JW, McDonald PC, Karar J, Hou Z, He
M, Kebebew E, Orntoft T, Herlyn M, Caton AJ, Fredericks W, Malkowicz B, Paterno CS, Carolin
AS, Speicher DW, Skordalakes E, Huang Q, Dedhar S, Borden KL, Rauscher FJ 3rd. LIMD2 is a
small LIM-only protein overexpressed in metastatic lesions that regulates cell motility and tumor
progression by directly binding to and activating the integrin-linked kinase. Cancer Res.
2014;74(5):1390-1403. PMID24590809
368. Arner E, Forrest AR, Ehrlund A, Mejhert N, Itoh M, Kawaji H, Lassmann T, Laurencikiene J,
Rydén M, Arner P, FANTOM Consortium (...Herlyn M...). Ceruloplasmin is a novel adipokine
which is overexpressed in adipose tissue of obese subjects and in obesity-associated cancer
cells. PLoS One. 2014;9(3):e80274. PMID24676332
369. Hasegawa Y, Tang D, Takahashi N, Hayashizah Y, Forrest AR, FANTOM Consortium
(…Herlyn M…), Suzuki H. CCL2 enhances pluripotency of human induced pluripotent stem cells
by activating hypoxia related genes. Sci Rep. 2014;4:5228. PMID24957798
370. Yang R, Zhend Y, Li L, Liu S, Spata M, Wei Z, Nace A, Herlyn M, Cui R, Guo W, Cotsarelis G, Xu
X. Direct conversion of mouse and human fibroblasts to functional melanocytes by defined
factors. Nat Comm. 2014;5:5807. PMID25510211
371. Cierlitza M, Chauvistre H, Bogeski I, Zhang X, Hauschild A, Herlyn M, Schadendorf D, Vogt T,
Roesch A. Mitochondiral oxidative stress as a novel therapeutic target to overcome intrinsic drug
resistance in melanoma subpopulations. Exp Dermatol. 2015;24:155-157. PMID25453510
372. Menon DR, Das S, Krepler C, Vultur A, Rinner B, Schauer S, Kashofer K, Wagner K, Zhang G,
Rad BE, Hass N, Soyer P, Gabrielli B, Somasundaram R, Hoefler G, Herlyn M, Schaider H. A
stress-induced early innate response causes multi-drug tolerance in melanoma. Oncogene. [Epub
ahead of print]. PMID25619837
373. Kraya AA, Piao S, Xu X, Zhang G, Herlyn M, Gimotty P, Levine B, Amaravadi RK, Speicher DW.
Identification of secreted proteins that reflect autophagy dynamics within tumor cells. Autophagy.
2015;11:60-74. PMID25484078
374. Webster MR, Xu M, Kinzler KA, Kaur A, Appleton J, O’Connell MP, Marchbank K, Valiga A, Dang
VM, Perego M, Zhang G, Slipicevic A, Keeney F, Lehrmann E, Wood W 3rd, Becker KG,
Kossenov AV, Frederick DT, Flaherty KT, Xu X, Herlyn M, Murphy ME, Weeraratna AT. Wnt5a
promotes and adaptive, senescence-like stress stress response, while continuing to drive invasion
in melanoma cells. Pigment Cell Melanoma Res. 2015;28:184-195. PMID25407936
375. Arner E, Daub CO, Vitting-Seerup K, Andersson R, Lilje B, Drablos F, Lennartsson, A,
Rönnerblad M, Hrydziuszko O, Vitezic M, Freeman TC, Alhendi A, Arner A, Axton R, Baillie JK,
Beckhouse A, Bodega B, Briggs J, Brombacher F, Davis M, Detmar M, Ehrlund A, Endoh M,
Eslami A, Fagiolini M, Fairbairn L, Faulkner GJ, Ferrai C, Fisher ME, Forrester L, Goldowitz D,
Guler R, Ha T, Hara M, Herlyn M, Ikawa T, Kai C, Kawamoto H, Khachigian L, Klinken PS, Kojima
S, Koseki H, Klein S, Mejhert N, Miyaguchi K, Mizuno Y, Morimoto M, Morris KJ, Mummery C,
Nakachi Y, Ogishima S, Okada-Hatakeyama M, Okazaki Y, Orlando Y, Ovchinnikov D, Passier R,
Patrikakis M, Pombo A, Qin XY, Roy S, Sato H, Savvi S, Saxena A, Schwegmann A, Sugiyama
D, Swoboda R, Tanaka R, Tomoiu A, Winteringham LN, Wolvetang E, Yanagi-Mizuochi C,
29
Curriculum Vitae for Meenhard Herlyn, D.V.M., D.Sc.
Yoneda M, Zabierowski S, Zhang P, Abugessaisa I, Bertin N, Diehl AD, Fukuda S, Furuno M,
Harshbarger J, Hasegawa A, Hori F, Ishikawa-Kato S, Ishizu Y, Itoh M, Kawashima T, Kojima M,
Kondo N, Lizio M, Meehan TF, Mungall CJ, Murata M, Nishiyori-Sueki H, Sahin S, Sato-Nagao S,
Severin J, de Hoon MJL, Kawai J, Kasukawa T, Lassmann T, Suzuki H, Kawaji H, Summers KM,
Wells C, Hume DA, Forrest ARR, Sandelin A, Carninci P, Hayashizaki Y. Gene regulation;
transcribed enhancers lead waves of coordinated transcription in transitioning mammalian cells.
2015 Feb 27;347(6225):1010-4. PMID25678556
376. Wang T, Xiao M, Ge Y, Krepler C, Belser E, Lopez-Coral A, Xu X, Zhang G, Azuma R, Liu Q, Liu
R, Li L, Amaravadi RK, Xu W, Karakousis G, Gangadhar TC, Schuchter LM, Lieu M, Khare S,
Halloran MB, Herlyn, M, Kaufman, R. BRAF inhibition stimulates melanoma-associated
macrophages to drive tumor growth. Cancer Res. 2015 [Epub ahead of print]. PMID25617424
377. Joshi S, Wels C, Beham-Schmid C, Fukunaga-Kalabis M, Holmen SL, Otte M, Herlyn M,
Waldhoer M, Schaider H. Galpha(13) mediates human cytomegalovirus-encoded chemokine
receptor US28 induced cell death in melanoma. Int J Cancer. Epub ahead of print, 6 Mar 2015.
PMID25754407
378. Fukunaga-Kalabis M, Hristova DM, Wang JX, Li L, Heppt MV, Wei Z, Gyurdiev A, Webster MR,
Oka M, Weeraratna AT, Herlyn M. UV-induced Wnt7a in the human skin microenvironment
specifies the fate of neural crest-like cells via suppression of Notch. J Invest Dermatol. Epub
ahead of print, 23 Feb 2015. PMID25705850
Research Publications, Peer-Reviewed Reviews
1.
Koprowski H, Herlyn M. Human tumor antigens. In: Wahren B, ed. Molecular Biology of Tumor
Cells. Raven Press; 1985:123-138.
2.
Ross AH, Herlyn M, Maul GG, Koprowski H, Bothwell M, Chao M, Pleasure D, Sonnenfeld KH.
The nerve growth factor receptor in normal and transformed neural crest cells. Ann N Y Acad Sci.
1986;486:115-123. v3032054
3.
Herlyn M, Clark WH, Rodeck U, Mancianti ML, Jambrosic J, Koprowski H. Biology of tumor
progression in human melanocytes. Lab Invest. 1987;56:461-474. PMID3553733
4.
Herlyn M, Rodeck U, Koprowski H. Shedding of human tumor-associated antigens in vitro and in
vivo. Adv Cancer Res. 1987;49:189-221. PMID3314394
5.
Herlyn M, Clark WHJ. Human melanoma: biology of tumor progression. The Melanoma Letter.
1987;5:3-4.
6.
Rodeck U, Menssen HD, Herlyn M. Growth factors in the pathogenesis of malignant diseases.
Dtsch Med Wochenschr. 1988;113:904-906. PMID3286186
7.
Herlyn M, Koprowski H. Melanoma antigens: immunological and biological characterization and
clinical significance. Annu Rev Immunol. 1988;6:283-308. PMID3289568
8.
Rodeck U, Herlyn M. Characteristics of cultured human melanocytes from different stages of
tumor progression. Cancer Treat Res. 1988;43:3-16. PMID2908575
9.
Kath R, Herlyn M. Molecular biology of tumor antigens. Curr Opin Immunol. 1989;1:863-866.
PMID2679733
10. Williams NN, Daly JM, Herlyn M. Primary colorectal carcinoma cell lines contain subpopulations
with invasive properties. Surgical Forum. 1989;40:400-403.
11. Herlyn M, Menrad A, Koprowski H. Structure, function, and clinical significance of human tumor
antigens. J Natl Cancer Inst. 1990;82:1883-1889. PMID2250310
12. Herlyn M. Human melanoma: development and progression. Cancer Metastasis Rev. 1990;9:101112. PMID2253310
13. Herlyn M, Kath R, Williams N, Valyi-Nagy I, Rodeck U. Growth-regulatory factors for normal,
premalignant, and malignant human cells in vitro. Adv Cancer Res. 1990;54:213-234.
PMID2404378
14. Valyi-Nagy I, Herlyn M. Melanocyte maturation and differentiation. Lab Invest. 1990;63:276-277.
15. Herlyn M, Malkowicz SB. Regulatory pathways in tumor growth and invasion. Lab Invest.
1991;65:262-271. PMID1890806
16. Rodeck U, Becker D, Herlyn M. Basic fibroblast growth factor in human melanoma. Cancer Cells.
1991;3:308-311. PMID1931440
30
Curriculum Vitae for Meenhard Herlyn, D.V.M., D.Sc.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
39.
40.
41.
Rodeck U, Herlyn M. Growth factors in melanoma. Cancer Metastasis Rev. 1991;10:89-101.
PMID1873858
Herlyn D, Linnenbach A, Koprowski H, Herlyn M. Epitope- and antigen-specific cancer vaccines.
Int Rev Immunol. 1991;7:245-257. PMID1779173
Valyi-Nagy IT, Herlyn M. Regulation of growth and phenotype of normal human melanocytes in
culture. Cancer Treat Res. 1991;54:85-101. PMID1673861
Herlyn D, Adachi K, Koprowski H, Herlyn M. Experimental model of human melanoma
metastases. Cancer Treat Res. 1991;54:105-118. PMID1673854
Graeven U, Rodeck U, Weinmann R, Herlyn M. Stable transfection of human malignant
melanoma cells with basic fibroblast growth factor antisense cDNA. Ann N Y Acad Sci.
1992;660:293-294. PMID1340139
Graeven U, Herlyn M. In vitro growth patterns of normal human melanocytes and melanocytes
from different stages of melanoma progression. J Immunother. 1992;12:199-202. PMID1445812
Menrad A, Herlyn M. Tumor progression, biology, and host response in melanoma. Curr Opin
Oncol. 1992;4:351-356. PMID1591308
Elder DE, Herlyn M. Antigens associated with tumor progression in melanocytic neoplasia.
Pigment Cell Res. 1992;3(suppl 2):136-143. PMID1409415
Shih IM, Herlyn M. Role of growth factors and their receptors in the development and progression
of melanoma. J Invest Dermatol. 1993;100:196S-203S. PMID8381840
Soballe PW, Herlyn M. Cellular pathways leading to melanoma differentiation: therapeutic
implications. Melanoma Res. 1994;4:213-223. PMID7950357
Herlyn M, Shih IM. Interactions of melanocytes and melanoma cells with the microenvironment.
Pigment Cell Res. 1994;7:81-88. PMID8066024
Nesbit M, Herlyn M. Adhesion receptors in human melanoma progression. Invasion Metastasis.
1994;14:131-146. PMID7657508
Shih IM, Herlyn M. Autocrine and paracrine roles for growth factors in melanoma. In Vivo.
1994;8:113-123. PMID7519892
Soballe PW, Daly JM, Herlyn M. Human carcinogenesis in SCID/human chimeras: a cutaneous
model. ACS Surgical Forum. 1994;65:559-561.
Herlyn M, Satyamoorthy K. Activated ras: yet another player in melanoma? Am J Pathol.
1996;149:739-744. PMID8780377 (PMC1865164)
Satyamoorthy K, Nesbit M, Hsu M-Y, Herlyn M. Utility of adenoviruses as gene expression
modules in melanoma. Biomedical and Health Res. 1996;12:71-77.
Hsu M-Y, Herlyn M. Cultivation of normal human epidermal melanocytes. In: Jones GE, ed.
Methods in Molecular Medicine: Human Cell Culture Protocols. Totowa, NJ: Humana Press;
1996:9-20.
Smalley KSM, Herlyn M. Towards the targeted therapy of melanoma. Mini-Rev Med Chem.
2006;6:109-120.
Satyamoorthy K, Herlyn M. Melanoma: molecular and cellular abnormalities. In: Bertino JR, ed.
Encyclopedia of Cancer II. San Diego, CA: Academic Press; 1997:1042-1050.
Sauter ER, Herlyn M. Molecular biology of human melanoma development and progression. Mol
Carcinog. 1998;23:132-143. PMID9833774
Meier F, Satyamoorthy K, Nesbit M, Hsu M-Y, Schittek B, Garbe C, Herlyn M. Molecular events in
melanoma development and progression. Front Biosci. 1998;3:D1005-1010. PMID9740553
Kamb A, Herlyn M. Malignant melanoma. In: Vogelstein B, Kinzler KW, eds. The Genetic Basis of
Human Cancer. New York, NY: McGraw-Hill Co.; 1998:507-518.
Nesbit M, Seatluri V, Herlyn M. Biology of melanocytes and melanoma. In: Balch C, Houghton A,
Sober AJ, Soong S, eds. Cutaneous Melanoma. St. Louis, MO: Quality Medical Publishing;
1998:463-473.
Satyamoorthy K, Meier F, Hsu M-Y, Berking C, Herlyn M. Human xenografts, human skin and
skin reconstructs for studies in melanoma development and progression. Cancer Metastasis Rev.
1999;18:401-405. PMID10721493
Hsu M-Y, Elder DE, Herlyn M. Melanoma: the Wistar melanoma (WM) cell lines. In: Masters JRW,
Palsson B, eds. Human Cell Culture, Vol. 3. London: Kluwer Academic Publishing; 2000:259-274.
31
Curriculum Vitae for Meenhard Herlyn, D.V.M., D.Sc.
42.
43.
44.
45.
46.
47.
48.
49.
50.
51.
52.
53.
54.
55.
56.
57.
58.
59.
60.
61.
62.
63.
64.
Herlyn M, Berking C, Li G, Satyamoorthy K. Lessons from melanocyte development for
understanding the biological events in naevus and melanoma formation. Melanoma Res.
2000;10:303-312. PMID10985664
Li G, Herlyn M. Dynamics of intercellular communication during melanoma development. Mol Med
Today. 2000;6:163-169. PMID10740255
Cascinelli N, Herlyn M, Schneeberger A, Kuwert C, Slominski A, Armstrong C, Belli F, Lukiewcz
S, Maurer D, Ansel J, Stingl G, Saida T. What is the most promising strategy for the treatment of
metastasizing melanoma? Exp Dermatol. 2000;9:439-451.
Herlyn M, Satyamoorthy K. Molecular biology of cutaneous melanoma. In: DeVita VTJ, Hellman
S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. 6th ed. Philadelphia, PA:
Lippincott Williams & Wilkins; 2000:2003-2012.
Berking C, Herlyn M. Human skin reconstruct models: a new application for studies of melanocyte
and melanoma biology. Histol Histopathol. 2001;16:669-674. PMID11332722
Satyamoorthy K, Bogenrieder T, Herlyn M. No longer a molecular black box—new clues to
apoptosis and drug resistance in melanoma. Trends Mol Med. 2001;7:191-194. PMID11325619
Gruss C, Herlyn M. Role of cadherins and matrixins in melanoma. Curr Opin Oncol. 2001;13:117123. PMID11224709
Berking C, Herlyn M. Experimental inductin of human atypical melanocytic lesions and melanoma
in ultraviolet-irradiated human skin grafted to immunodeficient mice. Methods Mol Med.
2001;61:71-84. PMID22323252
Kamb A, Herlyn M. Malignant melanoma. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The
Metabolic and Molecular Bases of Inherited Disease. New York, NY: McGraw-Hill Co.; 2001:967977.
Hsu M-Y, Meier F, Herlyn M. Melanoma development and progression: a conspiracy between
tumor and host. Differentiation. 2002;70:522-536. PMID12492494
Herlyn M, Padarathsingh M, Chin L, Hendrix M, Becker D, Nelson M, DeClerck Y, McCarthy J,
Mohla S. New approaches to the biology of melanoma: a workshop of the National Institutes of
Health Pathology B Study Section. Am J Pathol. 2002;161:1949-1957. PMID12414540
Bogenrieder T, Herlyn M. Cell-surface proteolysis, growth factor activation and intercellular
communication in the progression of melanoma. Crit Rev Oncol Hematol. 2002;44:1-15.
PMID12398996
Satyamoorthy K, Herlyn M. Cellular and molecular biology of human melanoma. Cancer Biol Ther.
2002;1:14-17. PMID12170758
Li G, Satyamoorthy K, Herlyn M. Dynamics of cell interactions and communications during
melanoma development. Crit Rev Oral Biol Med. 2002;13:62-70. PMID12097238
Ruiter D, Bogenrieder T, Elder D, Herlyn M. Melanoma-stroma interactions: structural and
functional aspects. Lancet Oncol. 2002;3:35-43. PMID11905603
Herlyn M. Emerging concepts and technologies in melanoma research. Melanoma Res.
2002;12:3-8. PMID11828252
Herlyn M, Guerry D. First international melanoma research congress. Cancer Biol Ther.
2003;2:721-724. PMID14688485
Smalley KS, Herlyn M. The great escape: another way for melanoma to leave physiological
control? J Invest Dermatol. 2003;121:xi-xii. PMID14632176
Bogenrieder T, Herlyn M. Axis of evil: molecular mechanisms of cancer metastasis. Oncogene.
2003;22:6524-6536. PMID14528277
Tuveson DA, Weber BL, Herlyn M. BRAF as a potential therapeutic target in melanoma and other
malignancies. Cancer Cell. 2003;4:95-98. PMID12957284
Liu ZJ, Herlyn M. Slit-Robo: neuronal guides signal in tumor angiogenesis. Cancer Cell. 2003;4:12. PMID12892705
Marincola FM, Wang E, Herlyn M, Seliger B, Ferrone S. Tumors as elusive targets of T-cell-based
active immunotherapy. Trends Immunol. 2003;24:335-342. PMID12810110
Li G, Satyamoorthy K, Meier F, Berking C, Bogenrieder T, Herlyn M. Function and regulation of
melanoma-stromal fibroblast interactions: when seeds meet soil. Oncogene. 2003;22:3162-3171.
PMID12789292
32
Curriculum Vitae for Meenhard Herlyn, D.V.M., D.Sc.
65.
66.
67.
68.
69.
70.
71.
72.
73.
74.
75.
76.
77.
78.
79.
80.
81.
82.
83.
84.
85.
86.
87.
88.
Velazquez OC, Herlyn M. The vascular phenotype of melanoma metastasis. Clin Exp Metastasis.
2003;20:229-235. PMID12741681
Satyamoorthy K, Herlyn M. p16INK4A and familial melanoma. Methods Mol Biol. 2003;222:185-195.
PMID12710687
Haass NK, Smalley KSM, Herlyn M. The role of altered cell-cell communication in melanoma
progression. J Mol Histol. 2004;35:309-318. SPRINGER35354
Perlis C, Herlyn M. Recent advances in melanoma biology. Oncologist. 2004;9:182-187.
PMID15047922
Haass NK, Smalley KS, Li L, Herlyn M. Adhesion, migration and communication in melanocytes
and melanoma. Pigment Cell Res. 2005;18:150-159. PMID15892711
Meier F, Schittek B, Busch S, Garbe C, Smalley K, Satyamoorthy K, Li G, Herlyn M. The
RAS/RAF/MEK/ERK and PI3K/AKT signaling pathways present molecular targets for the effective
treatment of advanced melanoma. Front Biosci. 2005;10:2986-3001. PMID15970553
Hsu M-Y, Rovinsky S, Penmatcha S, Herlyn M, Muirhead D. Bone morphogenetic proteins in
melanoma: angel or devil? Cancer Metastasis Rev. 2005;24:251-263. PMID15986135
Hsu M-Y, Li L, Herlyn M. Cultivation of normal human epidermal melanocytes in the absence of
phorbol esters. Methods Mol Med. 2005;107:13-28. PMID15492362
Fang D, Herlyn M. The transformed phenotype of melanocytes. In: Nordlund JI, Boissy RE,
Hearing VJ, King RA, Oetting WS, Ortonne J-P, eds. The Pigmentary System: Physiology and
Pathophysiology. 2nd ed. Madden, MA: Wiley-Blackwell; 2006:489-496.
Herlyn M. Molecular targets in melanoma: strategies and challenges for diagnosis and therapy. Int
J Cancer. 2006;118:523-526. PMID16258898
Smalley KS, Herlyn M. Targeting intracellular signaling pathways as a novel strategy in melanoma
therapeutics. Ann N Y Acad Sci. 2005;1059:16-25. PMID16382039
Haass NK, Herlyn M. Normal human melanocyte homeostasis as a paradigm for understanding
melanoma. J Investig Dermatol Symp Proc. 2005;10:153-163. PMID16358819
Smalley KS, Lioni M, Herlyn M. Targeting the stromal fibroblasts: a novel approach to melanoma
therapy. Expert Rev Anticancer Ther. 2005;5:1069-1078. PMID16336098
Smalley KS, Brafford PA, Herlyn M. Selective evolutionary pressure from the tissue
microenvironment drives tumor progression. Semin Cancer Biol. 2005;15:451-459.
PMID16043361
Smalley KS, Herlyn M. Towards the targeted therapy of melanoma. Mini Rev Med Chem.
2006;6:387-393. PMID16613575
Cher ML, Towler DA, Rafii S, Rowley D, Donahue HJ, Keller E, Herlyn M, Cho EA, Chung LWK.
Cancer interactions with the bone environment: a workshop of the National Institutes of Health
Tumor Microenvironment Study Section. Am J Pathol. 2006;168:1405-1412. PMID1665160
Smalley KSM, Lioni M, Herlyn M. Life isn’t flat: taking cancer biology to the next dimension. In
Vitro Cellular & Develop Biol Animals. 2006;42:242-247. PMID17163781
Lee JT, Herlyn M. Microenvironment influences melanoma progression. J Cell Biochem.
2007;101:862-872. PMID17171636
Smalley KS, Herlyn M. Malignant melanoma. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds.
The Online Metabolic and Molecular Bases of Inherited Disease. Heidelberg: Springer; 2007:1-27.
Pinnix CC, Herlyn M. The many faces of Notch signaling in skin-derived cells. Pigment Cell Res.
2007;20:458-465. PMID17935489
Herlyn M, Halaban R, Ronai Z, Schuchter L, Berwick M, Pinkel D. Roadmap for new opportunities
in melanoma research. Semin Oncol. 2007;34:566-576. PMID18086289
Zabierowski S, Herlyn M. Role of stem cells in melanoma progression: hopes for a better
treatment. Expert Rev Dermatol. 2007;2:191-201.
Lee JT, Herlyn M. Old disease, new culprit: tumor stem cells in cancer. J Cell Physiol.
2007;213:603-609. PMID17873516
Gaddipati H, Herlyn M. Association of polymorphisms of FAS-1377, FAS-670, and FASL-844
genes with risk factors for cutaneous malignant melanoma. Cancer J. 2007;13:226-228.
PMID1776275
33
Curriculum Vitae for Meenhard Herlyn, D.V.M., D.Sc.
89.
90.
91.
92.
93.
94.
95.
96.
97.
98.
99.
100.
101.
102.
103.
104.
105.
106.
107.
108.
109.
110.
111.
Smalley KSM, Lioni M, Noma K, Haass NK, Herlyn M. In vitro three-dimensional tumor
microenvironment models for anticancer drug discovery. Expert Opinion Drug Discov. 2008;3:110. (PMC N/A)
Zabierowski SE, Herlyn M. Melanoma stem cells: the dark seed of melanoma. J Clin Oncol.
2008;26:2890-2894. PMID18539969 (PMC N/A)
Roesch A, Herlyn M. Melanoma stem cells. In: Farrar W, ed. Cancer Stem Cells. Cambridge
University Press; 2010:1-48. (PMC N/A)
Haass NK, Hoeller C, Herlyn M. Targeting signaling pathways—in the search of melanoma’s
Achilles’ heel. In: Bar-Eli M, ed. Regulation of Gene Expression in the Tumor Environment.
Springer; 2008:27-42. (PMC N/A)
Villanueva J, Herlyn M. Melanoma and the tumor microenvironment. Curr Oncol Rep.
2008;10:439-446. PMID18706274 (PMC N/A)
Smalley K, Herlyn M. Integrating tumor-initiating cells into the paradigm for melanoma targeted
therapy. Int J Cancer. 2009;124:1245-1250. PMID19089923 (PMC N/A)
Villanueva J, Herlyn M. Melanoma. In: Encyclopedia of Life Sciences (eLS). John Wiley & Sons;
2009. (PMC N/A)
Santiago-Walker A, Li L, Herlyn M. Melanocytes: from morphology to application. Skin Pharmacol
Physiol. 2009;22:114-121. PMID19188759 (PMC N/A)
Herlyn M. Driving in the melanoma landscape. Exp Dermatol. 2009;18:506-508. PMID19366372
(PMC N/A)
Fukunaga-Kalabis M, Santiago-Walker A, Herlyn M. Matricellular proteins produced by
melanocytes and melanomas: in search for functions. Cancer Microenvironment. 2008;1:93-102.
PMID19308688 (PMC2654351)
Zabierowski SE, Herlyn M. Embryonic stem cells as a model to study melanocyte development.
Methods Mol Biol. 2010;584:301-316. PMID19907984 (PMC N/A)
Gaddipati H, Herlyn M. Melanoma: mutations in multiple pathways at the tumor-stroma interface.
In: Thomas-Tikhoenenko A, ed. Cancer Genome and Tumor Microenvironment. New York, NY:
Springer, 2010; 455-470. (PMC N/A)
Zabierowski SE, Fukunaga-Kalabis M, Li L, Herlyn M. Dermis-derived stem cells: a source of
epidermal melanocytes and melanoma? Pigment Cell Melanoma Res. 2011;24:422-429.
PMID21410654 (PMC N/A)
Vultur A, Villanueva J, Herlyn M. Targeting BRAF in advanced melanoma: a first step towards
manageable disease. Clin Cancer Res. 2011;17:1658-1663. PMID21447722 (PMC3079374)
Fukunaga-Kalabis M, Roesch A, Herlyn M. From cancer stem cells to tumor maintenance cells. J
Invest Dermatol. 2011;131:1600-1604. PMID21654838 PMC(3471358)
Villanueva J, Vultur A, Herlyn M. Resistance to BRAF inhibitors: unraveling mechanisms and
future treatment options. Cancer Res. 2011;71:7137-7140. PMID22131348 (PMCID3588168)
Zhang G, Herlyn M. Tumor microenvironment for melanoma cells. In: Bosserhoff A, ed. Melanoma
Development. New York: Springer; 2011:297-308. (PMC N/A)
Herlyn M, Villanueva J. Sorting through the many opportunities for melanoma therapy. Pigm Cell
Melanoma Res. 2011;24:975-7. PMID21899726 (PMC N/A)
Li L, Fukunaga-Kalabis M, Herlyn M. Isolation and cultivation of dermal stem cells that
differentiate into functional melanocytes. Methods Mol Biol. 2012;806:15-29. PMID22057442
(PMC N/A)
Bogenrieder T, Herlyn M. The molecular pathology of cutaneous melanoma. Cancer Biomark.
2011;9:267-286. PMID22112480 (PMC N/A)
Lee JT, Herlyn M. MEK’ing the most of p53 reactivation therapy in melanoma. J Invest Dermatol.
2012;132:263-265. PMID22241441 (PMC N/A)
Slipcevic A, Herlyn M. Narrowing the knowledge gaps for melanoma. Upsala J Med Sci.
2012;117:237-243. PMID22339359 (PMC3339555)
Maurer M, Somasundaram R, Herlyn M, Wagner SN. Immunotargeting of tumor subpopulations in
melanoma patients: a paradigm shift in therapy approaches. Oncoimmunology. 2012;1:14541456. PMID23243627 (PMC3518536)
34
Curriculum Vitae for Meenhard Herlyn, D.V.M., D.Sc.
112. Somasundaram R, Villanueva J, Herlyn M. Intratumoral heterogeneity as a therapy resistance
mechanism: role of melanoma subpopulations. Advances Pharmacol. 2012;65:335-359.
PMID2259031 (PMC in Process by Elsevier)
113. Facombre N, Nakagawa H, Herlyn M, Basu D. Stem-like therapy and therapy resistance in
squamous cell carcinoma. Advances in Pharmacol. 2012;65:359-365. PMID22959028 (PMC in
Process by Elsevier)
115. Swoboda R, Herlyn M. There is a world beyond proteIn mutations: the role of nonocoding RNAs in
melanomagenesis. Exp Dermatol. 2013;22:303-306. PMID23489578 (PMC3637432 [Available on
2014/5/1]; NIHMS445771)
116. Li L, Fukunaga-Kalabis M, Herlyn M. Isolation, characterization and differentiation of human multipotent dermal stem cells. Methods Mol Biol. 2013;989:235-246. PMID234838399
117. Merlino G, Flaherty K, Acquavella N, Day CP, Aplin A, Homen S, Topalian S, Van Dyke T, Herlyn
M. The future of preclinical mouse models in melanoma treatment is now. Pigm Cell Mel Res.
2013;26:E8-E14. PMID23531109
118. Slipicevic A, Somasundaram S, Sproesser K, Herlyn M. Isolation of melanoma subpopulations
using negative selection. Methods Mol Biol. 2014;1102:501-512. PMID24258995
119. Vultur A, Smalley K, Herlyn M. Melanoma. In: Gelman EP, Sawyer CL, Rauscher III FJ, eds.
Molecular Oncology: Causes of Cancer and Targets for Treatment. West Nyack, NY: Cambridge
University Press; 2014:698-703.
120. Liu J, Fukunaga-Kalabis M, Li L, Herlyn M. Developmental pathways activated in melanocytes
and melanoma. Arch Biochem Biophys. 2014;563C:13-21. PMID25109840
121. Schadendorf D, Fisher D, Garbe C, Gershenwald JE, Grob J-J, Halpern A, Herlyn M, Marchetti
MA, McArthur G, Ribas A, Roesch A, Hauschild A. Melanoma. Nature Reviews, in press.
Research Publications, Non-Peer Reviewed
1.
Guerry D, Alexander MA, Fuhrer JP, Herlyn M, Mitchell KF. HLA-DR-dependent autologous T-cell
proliferation induced by cultured primary melanoma. In: Seji M, ed. Phenotypic Expression in
Pigment Cells. Tokyo, Japan: University of Tokyo Press; 1981:547-553.
2.
Mach JP, Forni M, Buchegger F, Carrel S, Ritschard J, Donath A, Herlyn M, Koprowski H. Use of
radiolabeled monoclonal antibodies against colon carcinoma for photoscanning detection of
tumors in patients. In: Raynaud C, ed. Nuclear Medicine and Biology IV. Paris, France: Pergamon
Press; 1982: 2292-2294.
3.
Holgersson J, Karlsson KA, Karlsson P, Ringqvist M, Stromberg N, Thurin J, Blaszczyk M, Herlyn
M, Steplewski Z, Koprowski H. Mouse monoclonal antibodies with specificity for human
melanoma cells are directed against hitherto unknown disialogangliosides. In: Chester MA,
Heinegard D, Lundblad A, Svensson S, eds. Glycoconjugates. Lund-Ronneby, Sweden: Rahms;
1983:856-858.
4.
Herlyn M, Blaszczyk M, Koprowski H. Immunodiagnosis of human solid tumors. In: Riethmueller
G, Koprowski H, Kleinst SV, Munk K, eds. Genes and Antigens in Cancer Cells: The Monoclonal
Antibody Approach, Vol. 19. Basel, Switzerland: S Karger Publications; 1984:160-170.
5.
DeFreitas E, Suzuki H, Herlyn D, Lubeck M, Sears H, Herlyn M, Koprowski H. Human antibody
induction to the idiotypic and anti-idiotypic determinants of a monoclonal antibody against a
gastrointestinal carcinoma antigen. Curr Top Microbiol Immunol. 1985;75-89.
6.
Herlyn M, Koprowski H. New tumor markers in human gastrointestinal cancer. In: Nakamura R,
Vito WR, Tucker ESI, eds. Clinical Laboratory Molecular Analyses: New Strategies in
Autoimmunity, Cancer and Virology. San Diego, CA: Grune and Stratton; 1985:129-143.
7.
Herlyn M. Tumor markers in human colorectal carcinoma. In: Clinical Laboratory Molecular
Analyses: Future Directions. San Diego, CA: Scripps Clinic and Research Foundation; 1985:8692.
8.
Herlyn M. Detection of tumor-associated antigens in sera of patients with early gastrointestinal
malignancies. In: Chatal JF, Danis M, eds. Monoclonal Antibodies in Oncology: Clinical
Application. Nantes, France: Nouvelles Editions Medicales Francaises; 1985:21-24.
9.
Steplewski Z, Blaszczyk M, Herlyn D, Herlyn M, Koprowski H. Effector cells in ADCC with antibreast cancer monoclonal antibodies. In: Ceriani RL, ed. Workshop on Monoclonal Antibodies and
Breast Cancer. San Francisco, CA: Martinus Nijhoff Publishing; 1985:134-149.
35
Curriculum Vitae for Meenhard Herlyn, D.V.M., D.Sc.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
Herlyn M, Steplewski Z, Herlyn D, Koprowski H. CO 17-1A and related monoclonal antibodies:
their production and characterization. Hybridoma. 1986;5(suppl 1):S3-10. PMID3744383
Clark WHJ, Herlyn M. Melanocyte differentiation. Lab Invest. 1987;57:600-601.
Herlyn M, Ross AH, Balaban G, Herlyn D, Thurin J, Rodeck U, Koprowski H. Cell biology of
melanoma and nonmalignant melanocytic lesions. In: Mackie RM, ed. Pigment Cell: Pathobiology
of Melanoma. Karger, Basel, Switzerland; 1987:166-181.
Kath R, Rodeck U, Menssen HD, Mancianti ML, Linnenbach AJ, Elder DE, Herlyn M. Tumor
progression in the human melanocytic system. Anticancer Res. 1989;9:865-872. PMID2554787
Mancianti ML, Herlyn M. Tumor progression in melanoma: the biology of epidermal melanocytes
in vitro. Carcinog Compr Surv. 1989;11:369-386. PMID2646021
Györfi T, Rodeck U, Herlyn M. Growth factors in melanoma. In: Biological Agents in the Treatment
of Melanoma and Other Cancers; 1990:501-510; Proceedings of the International Conference,
Newcastle, Australia.
Juhasz I, Herlyn M. Stage-related structures on melanoma cells. In: Hersey P, ed. Biological
Agents in the Treatment of Melanoma and Other Cancers; 1990:256-267; Proceedings of the
International Conference, Newcastle, Australia.
Rodeck U, Herlyn M. Growth regulation in normal and malignant melanocytes. In: Paukovits WR,
ed. CRC Uniscience: Growth Regulation and Carcinogenesis. Boca Raton, FL: CRC Press;
1990:243-250.
Graeven U, Becker D, Herlyn M. Structural and functional characteristics of human melanoma. In:
Pretlow TG, Pretlow TP, eds. Biochemical and Molecular Aspects of Selected Cancers. Orlando,
FL: Academic Press; 1991:151-176.
Herlyn M, Houghton AN. Biology of melanocytes and melanoma. In: Balch C, Houghton A, Milton
G, Sober A, eds. Cutaneous Melanoma. Philadelphia, PA: Lippincott Co.; 1991:82-92.
Litwack G, Robertson NM, Maksymowych AB, Herlyn M. Vitamin B6 and other inhibitors of
glucocorticoid receptor function and cell-death of B16 melanoma cells. In: Jacobs MM, ed.
Vitamins and Minerals in the Prevention and Treatment of Cancer. Boca Raton, FL: CRC Press;
1991:19-30.
Valyi-Nagy I, Rodeck U, Kath R, Mancianti ML, Clark WH, Herlyn M. The human melanocyte
system as a model for studies on tumor progression. Basic Life Sci. 1991;57:315-326, discussion
326-318. PMID1814292
Houghton AN, Herlyn M, Ferrone S. Melanoma antigens. In: Balch C, Houghton A, Milton G,
Sober A, eds. Cutaneous Melanoma. Philadelphia, PA: Lippincott Co; 1992:130-143.
Miller EJ, Herlyn M. The basement membrane in benign and malignant melanocytic lesions. In:
Rabes H, Peters PE, Karger S, Munk K, eds. Contributions to Oncology. Basel, Switzerland:
Karger; 1992:269-282.
Herlyn M. Molecular biology of the melanoma cell surface - translational opportunities. Hem/Onc
Annals. 1993;1:251-255.
Györfi T, Herlyn M. Melanocyte and melanoma cell lines. In: Hay RJ, ed. The Atlas of Human
Tumor Cell Lines. San Diego, CA; Academic Press; 1994:413-428.
Herlyn M. Molecular genetics, immunology and experimental pathology of melanoma. Report
presented at: International Melanoma Conference; Brisbane, Australia: April 6-9, 1994. Melanoma
Res. 1994;4:331-336. PMID7858419
Herlyn M, Schuchter L. Gene therapy of melanoma: strategies and perspectives. Skin Cancer J.
1996;14:92-93.
Puri N, Herlyn M. Melanoma: effects of growth factors. In: Miller SJ, Maloney ME, eds. Cutaneous
Oncology: Pathophysiology, Diagnosis, and Treatment. Cambridge, MA: Blackwell Sci Inc.; 1996.
Dignat-George F, Bardin N, Combes V, Figarella-Branger D, Frances V, Herlyn M, Johnson JP,
Lepidi H, Mutin M, Vewton J, Pickl WF, Schneemann M, Simmons D, Simoni J, Sampol J. CD146
(S-ENDO/Muc18). In: Kishimoto T, Goyert S, Kikutani H, et al, eds. Leucocyte Typing VI: White
Cell Differentiation Ags. New York, NY: Garland Publishing Inc.; 1997:755-759.
Steplewski Z, Blaszczyk M, Herlyn D, Herlyn M, Koprowski H. Effector cells in ADCC with antibreast cancer monoclonal antibodies. In: Ceriani RL, ed. Monoclonal Antibodies and Breast
Cancer. Hingham, MA: Martinus Nijhoff Publishing; 1997:134-139.
36
Curriculum Vitae for Meenhard Herlyn, D.V.M., D.Sc.
31.
32.
33.
34.
35.
36.
37.
38.
39.
40.
41.
42.
43.
44.
45.
46.
47.
48.
49.
50.
51.
52.
53.
54.
55.
56.
Herlyn M. Endothelial cells as targets for tumor therapy. J Immunother. 1999;22:185.
PMID10335478
Berking C, Herlyn M. The role of UV in melanomagenesis. In: Ortonne J-P, Ballotti R, eds.
Mechanisms of Sun Tanning. London, England: Martin Dunitz Publications; 2002:327-332.
Bogenrieder T, Elder DE, Herlyn M. Molecular and cellular biology. In: Balch CM, Houghton AN,
Sober AJ, Soong S-J, eds. Cutaneous Melanoma. 4th ed. St. Louis, MO: Quality Medical
Publications; 2003:713-751.
Ruiter GJ, Herlyn M. [Melanoma-stroma interactions and melanoma progression]. J Dtsch
Dermatol Ges. 2003;1:773-776.
Smalley KS, Herlyn M. Loitering with intent: new evidence for the role of BRAF mutations in the
proliferation of melanocytic lesions. J Invest Dermatol. 2004;123:xvi-xvii. PMID15373800
Brafford P, Herlyn M. Gene expression profiling of melanoma cells−searching the haystack. J
Transl Med. 2005;3:2. PMID15649323 (PMC545940)
Herlyn M. Metatastic melanoma cells: introduction. Cancer Metastasis Rev. 2005;24:193-194.
PMID15986131
Li G, Herlyn M. Information sharing and collateral damage. Trends Mol Med. 2005;11:350-352.
PMID16002338
Liu ZJ, Herlyn M. Molecular biology of cutaneous melanoma. In: DeVita VTJ, Hellman S,
Rosenberg SA, eds. 7th ed. Cancer: Principles and Practice of Oncology. Philadelphia, PA:
Lippincott Williams & Wilkins; 2005:1745-1753.
Pinnix CC, Kogan M, Herlyn M. Melanoma stem cells: have we overlooked them? Mel Letter.
2005;23:3-4.
Lee JT, Herlyn M. Preventing metastasis: a LOX to learn. Cellscience Rev. 2006;3.
Lee JT, Herlyn M. Embryogenesis meets tumorigenesis. Nature Med. 2006;12:882-884.
PMID16892028
Smalley KSM, Herlyn M. Is knowledge about the genetic and epigenetic alterations in melanoma
a basis for targeted therapy? Exp Dermatol. 2007;15:844-845.
Smalley KSM, Herlyn M, Flaherty KT. Targeting BRAF/MEK inhibitors in melanoma therapy: new
hope or another false dawn? Exp Rev Derm. 2007;2:179-190.
Herlyn M. Farming cells to rebuild skin and melanoma. Cancer Biol Ther. 2007;6:467-471.
PMID17374983
Fukunaga-Kalabis M, Li L, Herlyn M. Three-dimensional culture of human skin. AACR Educational
Book from the AACR Annual Meeting; 2007:203-206.
Fukunaga-Kalabis M, Herlyn M. Unraveling mysteries of the multifunctional protein SPARC. J
Invest Dermatol. 2007;127:2497-2498. PMID17934501
Basu D, Herlyn M. Salmonella Typhimurium and a novel RNA interference vector for cancer gene
therapy. Cancer Biol Therap. 2008;7:151-152. PMID18347415 (PMC N/A)
Zabierowski SE, Herlyn M. Learning the ABCs of melanoma-initiating cells. Cancer Cell.
2008;13:185-187. PMID18328422 (PMC N/A)
Possik P, Lee JT, Herlyn M. Transforming the melanocyte: more than just MAPK. Bioforum Eur.
2008;2:1-3. (PMC N/A)
Lee JT, Brafford P, Herlyn M. Unraveling the mysteries of IGF-1 signaling in melanoma. J Invest
Dermatol. 2008;128:1358-1360. PMID18478012 (PMC N/A)
Vultur A, Herlyn M. Cracking the system: melanoma complexitiy demands new therapeutic
approaches. Pigm Cell Mel Res. 2009;22:4-5. PMID19054340 (PMC N/A)
Passague E, Rafii S, Herlyn M. Cancer stem cells are everywhere. Nature Med. 2009;15:23.
PMID19129778 (PMC N/A)
Basu D, Herlyn M. Defining microenvironments within mouse models that enhance tumor
aggressiveness. Cancer Biol Ther. 2009;8:4. PMID19182538 (PMC N/A)
Fisher DE, Barnhill R, Hodi FS, Herlyn M, Merlino G, Medrano E, Bastian B, Landi MT, Sosman J.
Melanoma from bench to bedside. Meeting report from the 6th International Melanoma Research
Congress. Pigm Cell Mel Res. 2010;23:14-26. PMID20025711 (PMC N/A)
Herlyn M, Fukunaga-Kalabis M. What is a good model for melanoma? J Invest Dermatol.
2010;130:911-912. PMID20231823 (PMC N/A)
37
Curriculum Vitae for Meenhard Herlyn, D.V.M., D.Sc.
57.
58.
59.
60.
61.
62.
63.
64.
65.
66.
67.
69.
70.
71.
72.
73.
74.
75.
76.
77.
Santiago-Walker A, Herlyn M. The ups and downs of transcription factors in melanoma. J Natl
Cancer Inst. 2010;102:1103-1104. PMID20660367 (PMC N/A)
Vultur A, Villanueva J, Herlyn, M. BRAF inhibitor unveils its potential against advanced
melanoma. Cancer Cell. 2010;18:301-302. (PMC N/A)
Herlyn M, Nathanson, K. Taking the guesswork out of uveal melanoma. New Engl J Med.
2010;263:2256-2257. PMID21083377 (PMC N/A)
Herlyn M, Bastian B. Pigm Cell Mel Res. 2010;23:834. PMID20973934 (PMC N/A)
Somasundaram R, Villanueva J, Herlyn M. Will engineered T cells expressing CD20 scFv
eradicate melanoma? Mol Ther. 2011;19:638-640. PMID21455210 (PMC3070110)
Herlyn M. New dream team for melanoma therapy. Pigm Cell Mel Res. 2012;25:279-280.
PMID22462086 (PMC N/A)
Somasundaram R, Herlyn M. Melanoma exosomes: messengers of metastasis. Nature Med.
2012;18:853-854. PMID22673991 (PMC N/A)
Herlyn M. Randy Lomax - the passionate melanoma advocate and champion of the Melanoma
Research Foundation. Pigm Cell Mel Res. 2012;25:832-833. PMID22702393 (PMC N/A)
Räsänen K, Herlyn M. Paracrine signaling between carcinoma cells and mesenchymal stem cells
generates cancer stem cell niche via epithelial-mesenchymal transition. Cancer Discov.
2012;2:775-779. PMID22969117 (PMC in Process by AACR)
Fukunaga-Kalabis M, Herlyn M. Beyond ABC: another mechanisms of drug resistance in
melanoma side population. J Invest Dermatol. 2012;132:2317-2319. PMID22971921 (PMC in
Process)
Zhang G, Herlyn M. Human nevi: no longer precursors of melanomas? J Invest Dermatol.
2012;132:2133-2134. PMID22895446 (PMC N/A)
Fukunaga-Kalabis M, Herlyn M. Cancer: complexion matters. Nature. 2012;491:342-343.
PMID23123853 (PMC N/A)
Somasundaram R, Herlyn M. Relapse of melanoma after successful adoptive T-cell therapy:
escape through inflammation-induced phenotypic melanoma plasticity. Pigm Cell Mel Res.
2013;26:2-4. PMID23387000 (PMC N/A)
Wang T, Somasundaram R, Herlyn M. Combination therapy of immunocytokines with Ipilumumab:
a cure for melanoma? J Invest Dermatol. 2013;133:595-596. PMID23399823 (PMC N/A)
Wang T, Herlyn M. The macrophage: a new factor in UVR-induced melanomagenesis. J Invest
Dermatol. 2013;133:1711-1713. PMID23760048
Vultur A, Herlyn M. Snapshot: melanoma. Cancer Cell. 2013;23:706. PMID23680152
Zhang G, Herlyn M. Linking SOX10 to slow-growth resistance phenotype. Cell Res. 2014;24:906907. PMID24853952
Somasundaram R, Herlyn M. Indomethacin to the rescue of TRAIL-resistant melanomas. J Invest
Dermatol. 2014;134:1198-1199. PMID24732334
Geserick P, Somasundaram R, Sproesser K, Herlyn M. Isolation of melanoma cell subpopulations
using negative selection. Methods Mol Biol. 2014;1102:501-512. PMID24258995
Slipicevic A, Herlyn M. KIT in melanoma: Many shades of grey. J Invest Dermatol. 2015;135:3378. PMID25573046
Books
Herlyn M. Molecular and Cellular Biology of Melanoma. Austin, TX: R.G. Landes Co; 1993.
PATENTS
1.
Detection of Colorectal Carcinoma
U.S. Patent #4,471,057
Issued:
September 11, 1984
Inventors: Hilary Koprowski, Zenon Steplewski, and Meenhard Herlyn
2.
Lewis Blood Group Phenotype Assay
U.S. Patent #4,607,009
Issued:
August 19, 1986
Inventors: Zenon Steplewski, Hilary Koprowski, and Meenhard Herlyn
38
Curriculum Vitae for Meenhard Herlyn, D.V.M., D.Sc.
3.
Monoclonal Anti-Ornithine Decarboxylase Antibody and Method of Producing Same
U.S. Patent #4,637,984
Issued:
January 20, 1987
Inventors: Thomas O’Brien, Anthony Pegg, and Meenhard Herlyn
4.
Diagnostic Method for Detection of Neural Crest Disease
U.S. Patent #4,786,593
Issued:
November 22, 1988
Inventors: Alonzo Ross, Hilary Koprowski, and Meenhard Herlyn
5.
Monoclonal Antibodies against Melanoma-Associated Antigens and Hybrid Cell Lines
Producing These Antibodies and Use Thereof
U.S. Patent #4,849,509
Issued:
July 18, 1989
Inventors: Jan Thurin, Hilary Koprowski, Zenon Steplewski, and Meenhard Herlyn
6.
Monoclonal Antibody to EGF Receptor
U.S. Patent #5,470,571
Issued:
November 28, 1995
Inventors: Meenhard Herlyn and Ulrich Rodeck
7.
WT1 Monoclonal Antibodies and Methods of Use Thereof
U.S. Patent #5, 622,835
Issued:
April 22, 1997
Inventors: Meenhard Herlyn, Frank Rauscher, Ulrich Rodeck, and Jennifer Morris
8.
Methods for Inducing Localized Vascular Development and Enhancing the Repair of a
Wound in the Mammalian Dermis
U.S. Patent #6,486,133
Issued:
November 26, 2002
Inventors: Meenhard Herlyn, Mark Nesbit, and Kapaettu Satyamoorthy
9.
Organotypic Culture of Colon and Usage Thereof
U.S. Patent #7,217,570
Issued:
May 15, 2007
Inventors: Meenhard Herlyn and Jiri Kalabis
10.
Multipotent Adult Stem Cells
U.S. Patent #60/671,025
Issued:
2005
Inventors: Xiao-Wei Xu, Hong Yu, Doug Fang, Meenhard Herlyn
11.
Methods and Composition for Monitoring Cell Migration and Identifying Clinically Relevant
Cytotoxic T Lymphocyte Activity
U.S. Patent #7,544,465
Issued:
June 9, 2009
Inventors: Dorothee Herlyn, Meenhard Herlyn
12.
Method for Dedifferentiating Melanocytes
PCT Application No PCT/US2009/058950
Issued:
September 30, 2009
Inventors: Meenhard Herlyn and Susan Zabierowski
13. Compositions Containing JARID1B Inhibitors and Methods for Treating Cancer
39
Curriculum Vitae for Meenhard Herlyn, D.V.M., D.Sc.
PCT Application No: 61/232,069
Issued:
August 7, 2009
Inventors: Meenhard Herlyn and Alexander Roesch
40
Download